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Stable expression of human groups IIA and X secreted
phospholipases A2 (hGIIA and hGX) in CHO-K1 and
HEK293 cells leads to serum- and interleukin-1-pro-
moted arachidonate release. Using mutant CHO-K1 cell
lines, it is shown that this arachidonate release does not
require heparan sulfate proteoglycan- or glycosylphos-
phatidylinositol-anchored proteins. It is shown that the
potent secreted phospholipase A2 inhibitor Me-Indoxam
is cell-impermeable. By use of Me-Indoxam and the cell-
impermeable, secreted phospholipase A2 trapping agent
heparin, it is shown that hGIIA liberates free arachido-
nate prior to secretion from the cell. With hGX-trans-
fected CHO-K1 cells, arachidonate release occurs before
and after enzyme secretion, whereas all of the arachido-
nate release from HEK293 cells occurs prior to enzyme
secretion. Immunocytochemical studies by confocal la-
ser and electron microscopies show localization of
hGIIA to the cell surface and Golgi compartment. Addi-
tional results show that the interleukin-1-dependent
release of arachidonate is promoted by secreted phos-
pholipase A2 expression and is completely dependent on
cytosolic (group IVA) phospholipase A2. These results
along with additional data resolve the paradox that ef-
ficient arachidonic acid release occurs with hGIIA-
transfected cells, and yet exogenously added hGIIA is
poorly able to liberate arachidonic acid from mamma-
lian cells.
Phospholipases A2 (PLA2s)
1 are a class of enzymes that re-
lease fatty acids from the sn-2 position of glycero-phospholip-
ids. Biomedical interest in these enzymes stems from the find-
ing that the liberation of arachidonic acid for the biosynthesis
of the eicosanoids (prostaglandins, leukotrienes, and others) is
mediated in mammalian cells by one or more PLA2s. Current
evidence favors a role for cytosolic phospholipase A2-
(cPLA2-, also known as group IVA PLA2) as a major compo-
nent of the arachidonate releasing signal transduction path-
way (1–3). Mammals also contain a large number of secreted
phospholipases A2 (sPLA2s) (4, 5), and the possible participa-
tion of these enzymes in arachidonate release is under active
investigation. For example, group V sPLA2 is present in the
macrophage-like cell line p388D1 and contributes a portion of
the arachidonate released in response to lipopolysaccharide (6).
Exogenous addition of groups V and X sPLA2s to a variety of
mammalian cells leads to arachidonate release (7–10). There is
some evidence to suggest that the action of cPLA2- is a pre-
requisite for sPLA2 function in cells (11, 12) and even for the
vice versa scenario (13–15), but such cross-talk between PLA2s
remains poorly understood.
To assess the arachidonate releasing capacity of PLA2s in
mammalian cells, CHO and HEK293 cell lines that stably
express the various enzymes have been established (16–20).
The behavior of human group IIA (hGIIA) and human group X
(hGX) sPLA2s when transfected in HEK293 and CHO cells has
been extensively studied. hGIIA is secreted from HEK293 cells,
and most of the extracellular enzyme is associated with the cell
surface. This sPLA2 is highly basic and is thought to bind to the
anionic heparan sulfate chains of cell surface glypican (21), a
GPI-linked proteoglycan. hGX is not a highly basic protein and
accumulates in the extracellular medium when transfected in
HEK293 cells (18). Whereas serum stimulates arachidonate
release from both hGIIA- and hGX-transfected HEK293 cells,
only the former cells show an additional increase in fatty acid
release if the pro-inflammatory cytokine interleukin-1 (IL-1)
is added along with serum (18). The biochemical basis for this
cytokine effect is not known. In this cell model, it has been
suggested that glypican-bound hGIIA is internalized into in-
tracellular punctate domains near the cell nucleus. That this is
due to import from the cell surface into caveolae and caveolae-
derived vesicles is proposed based on confocal microscopy stud-
ies showing punctate co-localization of hGIIA and caveolin-2
throughout the cytosol including the perinuclear region (21).
These observations raise the possibility that the site of fatty
acid release by hGIIA is within intracellular vesicles. In con-
trast, the non-heparan sulfate-binding hGX is thought to act on
the extracellular face of the plasma membrane of HEK293 cells
and does not accumulate in intracellular domains (18). It is not
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yet known whether there is a biochemical connection between
IL-1-induced arachidonate release and intracellular action of
hGIIA.
The possibility that hGIIA acts on a cellular membrane other
than the extracellular face of the plasma membrane is appeal-
ing. This is because the extracellular face of the mammalian
cell plasma membrane is rich in the zwitterionic phospholipids
phosphatidylcholine and sphingomyelin, and it is well estab-
lished that hGIIA displays extremely low enzymatic activity
toward phosphatidylcholine-rich vesicles in vitro because this
enzyme cannot bind to the zwitterionic interface (22, 23). In-
deed, relatively large amounts (typically 10 g/ml) of hGIIA
need to be added exogenously to mammalian cells, including
HEK293 cells, to cause detectable arachidonate release (23).
Thus, it was surprising to find that HEK293 cells stably trans-
fected with hGIIA, which produce ng/ml amounts of enzyme,
are able to liberate arachidonate. This suggests that hGIIA
releases arachidonic acid within a membrane compartment
that is accessible to enzyme produced by transfection but not by
enzyme added exogenously to cells. The very poor ability of
exogenously added hGIIA to liberate arachidonic acid from
HEK293 cells is seemingly at odds with the glypican-shuttling
model described above. One would anticipate that exogenously
added hGIIA would bind to the heparan sulfate chains of cell
surface glypican and be imported into caveolae and caveolae-
derived vesicles. For example cholera toxin readily labels
caveolae when added exogenously to mammalian cells (24).
Perhaps hGIIA must be preloaded onto glypican during the
secretory process, and exogenously added hGIIA cannot access
the heparan sulfate chains of cell surface glypican. But it is
difficult to conceive that amounts of exogenously added hGIIA
3 orders of magnitude higher than those produced by trans-
fected HEK293 cells would not lead to loading of cell surface
heparan sulfate chains. It is this paradox that prompted us to
further investigate the mode of action of hGIIA in transfected
CHO and HEK293 cells.
In marked contrast to hGIIA, hGX binds with high affinity to
phosphatidylcholine-rich membranes in vitro (23), and ng/ml
amounts of exogenously added hGX are sufficient to liberate
arachidonic acid from HEK293 cells and other mammalian
cells (8, 9, 25). Given these observations and the fact that hGX
does not bind to heparan sulfate, it has been suggested that
hGX acts on the extracellular face of the plasma membrane
once secreted from hGX-transfected HEK293 cells (18). Thus,
we also included hGX-transfected CHO and HEK293 cells in
side-by-side comparative studies with hGIIA-transfected cells.
Our results show that arachidonate release by hGIIA in trans-
fected CHO and HEK293 cells occurs prior to secretion to the
extracellular fluid. Arachidonate release by hGX occurs before
and after secretion from CHO cells and prior to secretion from
HEK293 cells. sPLA2 action prior to secretion resolves the
paradox of why hGIIA is able to release arachidonic acid in
transfected cells but not when added exogenously to cells.
EXPERIMENTAL PROCEDURES
Materials—The cPLA2- inhibitors pyrrophenone (26), pyrrolidine-1
(27), and AZ-1 (compound 22 of (28)) and the sPLA2 inhibitor Me-
Indoxam (29) were prepared as described. Porcine intestinal mucosa
low molecular mass heparin (3,000 Da) and heparin are from Sigma
(H3400 and H3149, respectively). The Golgi-specific probe NBD-C6-
ceramide is from Molecular Probes (Eugene, OR). pgsA-745 and GPI-
LA1 CHO cells were obtained as gifts from J. Esko (University of
California) and F. G. van der Goot (University of Geneva), respectively.
The synthesis of Me-Indoxam radiolabeled in the benzylic position,
[3H]Me-Indoxam, is given in the Supplemental Material. [3H]Arachido-
nate (200 Ci/mmol) is from American Radiochemicals Inc. Human re-
combinant IL-1 is from R & D Systems and was used from small frozen
aliquots, thus avoiding freeze-thaw cycles. Recombinant human
cPLA2- was prepared as described (30), and anti-cPLA2- antisera
were obtained from C. C. Leslie (National Jewish Medical Research
Center) and M. Wakelam (University of Birmingham).
Cell Culture and Preparation of Stable Transfectants—CHO-K1 and
HEK293 cells were obtained from the American Type Culture Collec-
tion and cultured at 37 °C in a humidified atmosphere of 5% CO2 in
Ham’s F-12 medium with 2 mM glutamine (Sigma N6658) containing
10% FBS for CHO-K1 cells and in RPMI 1640 medium with 2 mM
glutamine (Invitrogen catalog number 11875–093) containing 10% FBS
for HEK293 cells. For both media, 2 mM glutamine was added to
working solution every 2 weeks. To prevent, cross-clone contamination,
pipette tips with cotton plugs were used when handling multiple cell
clones. The cells were split using trypsin/EDTA (trypsin was removed
from the cell monolayer prior to adding fresh medium to minimize the
degradation of cell surface proteins).
The plasmid for hGIIA expression, pRc-CMV/neo-hGIIA, contains
the sequence GCGGCCGCC-ATG-hGIIA-TGA-TAAAGATCT (the NotI
and XbaI sites are underscored, the full-length hGIIA cDNA from start
to stop codon is italicized) ligated into the NotI and XbaI sites of the
pRc-CMV/neo vector (Invitrogen). The plasmid for hGX expression,
pRc-CMV/neo-hGX, contains the sequence GCGGCCGCC-ATG-hGX-
TGA-TCTAGA. Note that the hGX cDNA contains two potential start
sites, and pRC-CMV/neo-hGX uses the downstream start site, which
corresponds to the sole start site of the mouse group X sPLA2 cDNA.
Thus, the N-terminal sequence of the hGX produced is MLLL. Plasmids
for transfection were prepared in endotoxin-free form from bacterial
cultures using the SNAP MidiPrep Kit (Invitrogen K1910-01), and DNA
was quantified by optical density at 260 nm. CHO-K1 cells were trans-
fected using OPTI-MEM® I Reduced Serum Medium and Lipo-
fectAMINE (both from Invitrogen) using the optimized procedure for
these cells provided by Invitrogen. Stable transfectants were selected
by limiting dilution in 96-well plates using medium containing 600
g/ml Geneticin (Invitrogen) (an antibiotic kill curve was carried out to
establish that this concentration was effective for selection). HEK293
cells were transfected as above except the optimized procedure for these
cells was used (provided by Invitrogen), and the Geneticin concentra-
tion was 500 g/ml. Maintenance cultures of stably transfected
CHO-K1 and HEK293 cells were routinely grown in medium containing
Geneticin, but antibiotic was omitted when cells were plated for studies
or during the initial plating of frozen stocks.
Site-specific mutagenesis was prepared using the QuikChange kit
(Stratagene), and full-length coding sequences were submitted to DNA
sequencing to verify that no additional mutations were introduced.
Arachidonic Acid Release Studies—CHO-K1 cells were plated at 5 
104 cells/ml in 24-well plates (Nunc catalog number 143982) (1 ml
medium/well). When cells reached 80% confluence, 0.1 Ci of
[3H]arachidonate was added per well, and the cells were placed in the
incubator for 20–24 h. The cells were washed three times with complete
medium (medium carefully removed with a pipette rather than by
aspiration) and then covered with 1 ml of medium containing the
desired additives (described in the figure legends). When IL-1 was
used, it was added from a freshly prepared stock of 0.1 ng/l in PBS
containing 0.2% bovine serum albumin. The cells were placed in the
incubator for the desired time. After the desired time, the medium was
removed and centrifuged for 7 min at 3,000 rpm to pellet any dislodged
cells. A 0.5-ml aliquot of the supernatant was submitted to scintillation
counting. To the cell pellet in the well was added 0.5 ml of trypsin/
EDTA, and the plate was placed in the incubator for 30 min. The cells
were resuspended by pumping the solution up and down several times
with a pipettor, and all of the liquid was submitted to scintillation
counting to give the cell-associated cpm. The percentage of [3H]arachi-
donate release to the medium was calculated as 100  (dpm in medi-
um)/(dpm in medium  cell associated dpm).
[3H]Arachidonate release from HEK293 cells was carried out by
plating cells in 24-well plates. When cells reached80% confluency, 0.1
Ci of [3H]arachidonate was added to 1 ml of complete medium in each
well. The cells were placed in the incubator for 20–24 h. The medium
was removed with a pipette, and the cells were covered with 1 ml of
complete medium. After 5–10 min the medium was removed, and the
cells were covered with 1 ml of medium containing the desired additives
(described in the figure legends). The cells were placed in the incubator
for the desired time period, and the percentage of total [3H]arachido-
nate released to the medium was determined as for CHO-K1 cells.
In some studies, the cells were extracted with organic solvent to
determine the amount of tritium in the neutral lipid fraction. The cells
were labeled with [3H]arachidonate and stimulated as described above.
After removal of the medium, the cell pellets were treated with trypsin/
EDTA as above, and the cell suspension was transferred to an Eppen-
dorf tube. An aliquot of the cell suspension (125 l) was transferred to
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a new Eppendorf tube, and 370 l of CHCl3, MeOH, 10 N HCl (200/200/1
by volume) was added followed by 460 l of CHCl3, MeOH, H2O (1/2/0.8)
and then 240 l of CHCl3, and finally 240 l of H2O. After mixing with
a vortex mixer for 1 min, the tubes were centrifuged for 2 min at
10,000  g to separate the solvent layers. Most of the lower layer was
transferred to a glass tube, and solvent was removed with a stream of
N2. Oleic acid (10 pmol) was added followed by 1 ml of low boiling
petroleum ether/ethyl ether/glacial acetic acid (70/30/1, by volume). The
sample was mixed on a vortex mixer for 30 s and loaded onto a small
column of silica gel in a glass wool-plugged Pasteur pipette. The eluant
was collected into a scintillation vial along with the eluant after wash-
ing the column with an additional 4 ml of the same solvent. The solvent
was removed with a stream of air, and the residue was submitted to
scintillation counting.
In some studies, the cells were extracted with organic solvent, and
the extract was analyzed for [3H]arachidonic acid after TLC on a silica
plate. The cells were labeled with [3H]arachidonate and stimulated as
described above. After removal of the medium, the cell pellets were
treated with trypsin/EDTA as above, and the cell suspension was trans-
ferred to an Eppendorf tube. A portion of the cell suspension was
extracted with organic solvent and prepared for silica gel chromatogra-
phy as described above. To the extract was added 50 g of nonlabeled
arachidonic acid, and the solution was spotted on one lane of a 20 
20-cm silica TLC plate. The plate was developed in a tank with n-
hexane/diethyl ether/glacial acetic acid (70:30:1 by volume). The arachi-
donic acid spot was located by placing the plate in a tank of iodine
vapor. The spot was scrapped from the plate, the silica was transferred
to a vial containing scintillation fluid and submitted to scintillation
counting.
sPLA2 Enzymatic Assay—sPLA2 enzymatic activity of cell culture
medium was measured using a variation of the fluorimetric assay (31).
The substrate, 1-palmitoyl-2-(10-pyrenedecanoyl)-sn-glycero-3-phos-
phoglycerol (Molecular Probes) was dissolved at 1 mg/ml in toluene/
isopropanol (1/1), and the concentration was determined from the ab-
sorbance at 342 nm ( 40,000 M1 cm1). A 0.2-ml aliquot of substrate
stock solution was concentrated to dryness with a stream of N2 followed
by the addition of 1 ml of absolute ethanol (any undissolved material
was removed by centrifugation at 14,000  g for 2 min). After rede-
termination of the substrate concentration, a working solution of sub-
strate mixture was prepared by diluting the ethanol stock of substrate
into 30 ml of buffer (50 mM Tris, 100 mM NaCl, 1 mM EGTA, pH 7.4)
while mixing on a vortex mixer to give a final substrate concentration of
1 M. The 1-ml assay mixture is prepared by mixing 980 l of substrate
mixture with 10 l of fatty acid free BSA (10 mg/ml, w/v in water;
Sigma) and 10 l of CaCl2 (1 M in water) in a fluorescence cuvette
equipped with a magnetic stir bar. After the addition of tissue culture
medium (typically 20–40 l for hGIIA and 100–200 l for hGX-trans-
fected cells) or recombinant sPLA2, the fluorescence was monitored
with excitation at 342 nm and emission at 395 nm at room temperature
with stirring. The assay is calibrated to give moles of product by the
addition of a standard solution of 10-pyrenedecanoic acid in ethanol to
the complete assay mixture lacking sPLA2.
Extraction of Cell Surface hGIIA with Salt—The cells were covered
with complete medium supplemented with various amounts of NaCl
(see figure legends). The cells were placed in the incubator for 15 min,
and then the medium was transferred to an Eppendorf tube and cen-
trifuged for 7 min and 3,000 rpm to pellet any dislodged cells. The
supernatant was submitted to the fluorimetric sPLA2 assay (see above)
or stored at 20 °C prior to assay.
Confocal Laser Fluorescence Microscopy—Cells for microscopy were
grown on nitric acid-washed coverslips (12-mm diameter, #1.5; Electron
Microscopy Sciences catalog number 72230-01, autoclaved before use)
to 50–60% confluence, stimulated if desired, and fixed as follows. The
medium was removed by aspiration, and the cells were washed once
with PBS at room temperature. The cells were covered with ice-cold
formaldehyde (3% w/v, prepared by dilution of an ampule of 16% form-
aldehyde; Electron Microscopy Sciences catalog number 15710, with
PBS). After 20 min at room temperature, the cells were washed three
times with PBS at room temperature. For permeabilization, Triton
X-100 (0.2% v/v in PBS) was added, and the cells were incubated at
room temperature for 10 min. The cells were washed twice with PBS
and then incubated for 10 min at room temperature with 1% BSA in
PBS. After removing the blocking agent, the cells were incubated for 2 h
at room temperature with 1% BSA containing anti-hGIIA antiserum
(1/500 dilution, antiserum prepared as described (2)). The cells were
washed three times with PBS and then incubated with 1% BSA in PBS
for 10 min at room temperature. After removing the blocking agent,
secondary antibody (1/200 dilution of affinity purified, fluorescein iso-
thiocyanate-conjugated, anti-rabbit IgG F(ab)2, Organon Teknika
Corp., Durham, NC) was added in 1% BSA in PBS. After 1 h at room
temperature, the cells were washed four times with PBS. Coverslips
were mounted on glass slides with mounting solution (0.1 M n-propyl
gallate in 9:1 glycerol:PBS) and sealed to the slide with nail polish. The
slides were viewed within 15 h with a Bio-Rad MRC-600 confocal
microscope equipped with a 60 oil immersion objective. NBD-C6 cer-
amide was used as a Golgi marker. CHO-K1 cells were fixed as de-
scribed above. After washing the cells, the coverslips were placed at
4 °C, and 1 ml of freshly prepared NBD-C6 ceramide (5 M in 1% BSA
in PBS) was added per well. After 30 min at 4 °C, the cells were washed
several times with 3% BSA in PBS to remove excess reagent and viewed
by confocal microscopy.
In some experiments the cells were permeabilized with saponin.
After the third PBS wash (see above), the cells were permeabilized with
1% saponin (w/v) (Sigma catalog number S7900), 1% (w/v) BSA in PBS
for 30 min at room temperature. The cells were washed once with 1%
BSA in PBS and then covered with 1% BSA in PBS containing the
primary antiserum. After a 1-h incubation at room temperature, the
cells were washed three times with 1% BSA in PBS at room tempera-
ture. The cells were covered with 1% BSA in PBS with the secondary
antibody and incubated at room temperature for 1 h. The cells were
washed four times with PBS at room temperature and prepared for
confocal microscopy as described above.
Electron Microscopy—hGIIA-transfected HEK293 cells (clone 1)
were grown in 10-cm dishes to 70% confluence. The medium was
removed and replaced with fresh complete medium with or without 4
ng/ml IL-1. After 4 h at 37 °C, the medium was removed, and the cell
layer was washed twice with PBS. In some experiments, the cells were
incubated with complete medium containing 0.5 mg/ml heparin for 20 h
at 37 °C in the presence or absence of IL-1. The cells were covered
either with PBS containing 8% paraformaldehyde (paraformaldehyde;
Electron Microscopy Sciences catalog number 15710). Fixation was
allowed to proceed for 2 h at room temperature. The fixative was
removed, and the cells were washed twice with PBS. The plates were
filled with PBS, covered, sealed with Parafilm, and stored at 4 °C until
processed further for electron microscopy (within 7 days). Fixed cells
were processed for frozen sectioning as described (32). The sections
were labeled with polyclonal antibodies to hGIIA (Cayman) followed by
10-nm protein A-gold (University of Utrecht, Utrecht, The Nether-
lands). For double labeling, sections were labeled with antibodies to
hGIIA PLA2 followed by 5-nm protein A-gold, fixed, and then labeled
with antibodies to caveolin 1 (Transduction Laboratories) followed by
10-nm protein A-gold.
Cell Permeability of Me-Indoxam—Uptake of Me-Indoxam into
HEK293 cells was measured by incubating cells with [3H]Me-Indoxam
(680 Ci/mol, prepared as described in the Supplemental Material) fol-
lowed by centrifugation of the cells through a layer of serum to rapidly
separate them from the extracellular medium (33). Nontransfected
HEK293 cells were dislodged from the plate with trypsin/EDTA and
washed two times with PBS. Trypsinized cells were washed three times
with 4–5 ml of PBS, and the cell number was determined with a
hemocytometer. The desired number of cells in 100 l of medium
without serum containing the indicated amount of radiolabeled com-
pound (see legend to Fig. 9S) were placed in the CO2 incubator at 37 °C
for 20 min. The solution was carefully layered onto 400 l of 100% FBS
in the bottom of a 0.5-ml Eppendorf tube, and the samples were cen-
trifuged at 10,000  g for 30 s in a swinging bucket rotor at room
temperature. The tubes were immediately placed in a dry ice/ethanol
bath, and the frozen tubes were cut with a razor blade (as a cutting
guide, the tube was placed in a 1.5-ml Eppendorf tube whose bottom
was cut so that the smaller tube protruded 2 mm from the bottom edge
of the larger tube). The tube bottom was placed in scintillation fluid to
determine the amount of radioactivity. Additional radioactive com-
pounds used were 1-[3H]-D-mannitol (20 Ci/mmol; American Radio-
chemicals Inc.) and 4-[3H]-L-propranolol (24.4 Ci/mmol; PerkinElmer
Life Sciences). Cell permeability of Me-Indoxam was also measured
using the Caco-2 (TC7 clone) cell monolayer assay using standard
procedures (details given as in the Supplemental Material).
Immunoblot Analysis of cPLA2-—This is described in the Supple-
mental Material.
RESULTS
Arachidonate Release in CHO-K1 Cells Transfected with
hGIIA and hGX—CHO-K1 cells were transfected with plas-
mids driving constitutive expression of hGIIA and hGX, and 12
stable transfectants were established. The culture medium
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from each clone was assayed for sPLA2 enzymatic activity
using a sensitive, real time fluorimetric assay. Five to six
hGIIA clones and hGX clones produced detectable sPLA2 enzy-
matic activity, and these clones were used for subsequent ex-
periments. The amount of [3H]arachidonate released into the
culture medium was determined after cells were cultured un-
der various conditions. The release of [3H]arachidonate is ex-
pressed as percentage of the total dpm (medium and cell asso-
ciated) that appears in the medium. In this way, fatty acid
release is normalized to remove differences because of varia-
tion in the amount of radiolabeled arachidonate incorporated
into cellular phospholipids and to variation in cell number/
culture well.
As shown in Fig. 1A, both nontransfected and hGIIA-trans-
fected CHO-K1 cells (clones 4 and 5 shown) liberate arachido-
nate into the medium in a time-dependent manner. FBS alone
and IL-1 alone increase arachidonate release slightly (1.3-
and 2-fold, respectively), and both together lead to a larger
release of arachidonate than that produced during stimulation
with either agent alone. Stable expression of hGIIA in CHO-K1
cells leads to higher arachidonate release than that produced in
nontransfected cells (Fig. 1A). The differential between trans-
fected and nontransfected cells is less than 2-fold but statisti-
cally significant; the data in Fig. 1A show the standard devia-
tion of triplicate experiments for each clone. Clone 4 liberates
more arachidonate than does clone 5, and this correlates with
the observation that clone 4 releases more hGIIA enzymatic
activity than clone 5 into the culture medium (inset in Fig. 1A).
These same trends in arachidonate release and sPLA2 enzy-
matic activity were observed in six independent experiments,
each done in triplicate. hGIIA-dependent increase in arachido-
nate release correlated to the amount of sPLA2 enzymatic
activity was also seen in the three other CHO-K1 clones exam-
ined (not shown).
We measured [3H]arachidonate released into the culture me-
dium by CHO-K1 cells. Albumin present in the culture medium
presumably serves as a sink by binding fatty acid; this was
further investigated with HEK293 cells (see below). We also
examined the cells for the presence of radiolabel in the neutral
lipid fraction. This was accomplished by extracting the cell
pellet with chloroform:methanol and passing the extract
through a small column of silica gel. For CHO-K1 cells in the
absence of FBS/IL-1 stimulation, 1.2  0.2% of the total
radioactivity is in the neutral lipid fraction, and this number
increases to 2.0  0.2% when cells are stimulated with FBS/
IL-1. The corresponding numbers for hGIIA-transfected
CHO-K1 cells (clone 1) are 1.2  0.2 and 1.8  0.2% in the
absence and presence of FBS/IL-1, respectively (1.0  0.1 and
1.8  0.2% for clone 4). Given these small values compared
with the amount of radioactivity released into the culture me-
dium and the fact that the numbers are independent of
whether the cells are transfected with hGIIA, we did not ex-
amine whether this cell-associated neutral lipid radioactivity is
due to free arachidonic acid, arachidonyl-triglyceride, or some
other neutral arachidonyl species.
CHO-K1 cells were also transfected with the hGIIA mutant
in which the catalytic site histidine has been changed to glu-
tamine (hGIIA-H47Q). Recombinant hGIIA-H47Q displays
2–4% of wild type enzymatic activity (34). Nine clones of
hGIIA-H47Q transfected CHO-K1 cells were stimulated with
FBS and IL-1 using the standard protocol, and the average
percentage of [3H]arachidonate release was 4.5  0.2% after
8 h. In a side-by-side analysis, nontransfected CHO-K1 cells
released 4.6  0.2% [3H]arachidonate (five independent meas-
urements) after 8 h, and hGIIA-transfected CHO-K1 cells
(clone 4) released 6  0.1% [3H]arachidonic acid (four inde-
pendent measurements) after 8 h. Thus, it is clear that enzy-
matically compromised hGIIA is not able to augment arachi-
donic acid release in these cells.
Although we could not assess the expression level of hGIIA-
H47Q by enzymatic assay, immunocytochemical analysis of
two clones studied by confocal immunofluorescence microscopy
of the clones showed qualitatively similar levels of hGIIA ex-
pression as clones expressing wild type hGIIA (see below).
Thus, the increase in arachidonate liberation shown in Fig. 1A
requires the expression of enzymatically active hGIIA.
We also established several clones of CHO-K1 stably trans-
FIG. 1. Arachidonate release by CHO-K1 cells transfected with
hGIIA (A) or hGX (B). Arachidonate release is expressed as a percent-
age of total [3H]arachidonate (medium  cell associated) released into
the medium after 4 or 8 h of culture in the presence and absence of FBS
and IL-1 (1 ng/ml) as indicated. Nontransfected CHO-K1 cells, clones
4 and 5 of hGIIA-transfected cells, and clones 5 and 6 of hGX-trans-
fected cells are shown. The amount of sPLA2 secreted into the culture
medium after 3 days of culture was quantified (see insets) by the
fluorimetric enzyme assay (after washing the cells with 1 M NaCl in the
case of hGIIA transfectants). The data shown are representative of six
independent experiments, each done in triplicate; the error bars show
the standard deviation from one of the triplicate analyses.
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fected with hGX, and arachidonate release data is shown for
clones 5 and 6 in Fig. 1B. Time-dependent arachidonate release
is seen for all clones, and as for hGIIA-transfectants, stimula-
tion of the cells with FBS and IL-1 leads to more arachidonate
release than that measured when either agent is added alone
(Fig. 1B). FBS/IL-1-stimulated arachidonate release was
more pronounced in hGX transfectants compared with hGIIA
transfectants (Fig. 1, compare A and B). hGX clone 6 produces
more arachidonate than hGX clone 5, which correlates with the
higher enzymatic activity measured in the culture medium of
clone 6 versus clone 5 cells (inset to Fig. 1B). The results in Fig.
1B were reproducible after six independent trials (each done in
triplicate). A similar correlation between enhanced [3H]arachi-
donate release and hGX expression level was seen in the three
additional hGX clones examined (not shown).
A Portion of Expressed hGIIA but Not hGX Is Cell Surface-
bound—CHO-K1 cells expressing hGIIA (clones 1, 4, and 5)
were cultured until confluent in medium containing FBS, and
the amount of hGIIA enzymatic activity in the culture medium
was quantified using the fluorimetric assay. After removal of
the medium, the cell layer was covered with medium contain-
ing 1 M NaCl for 15 min at 37 °C, and additional hGIIA was
recovered in the salt wash. It was found that 47  10% of the
total recovered enzyme was liberated into the culture medium
in the absence of salt. These results suggest that approximately
half of the secreted hGIIA is electrostatically bound to one or
more anionic components on the cell surface. This is presum-
ably due to the fact that hGIIA is a highly cationic protein, with
23 surface lysine and arginine residues (calculated pI of 9.4).
Consistent with this electrostatic attachment, much more,
94  5% (average of three experiments), of the mutant hGIIA
in which three basic residues have been mutated to anionic
residues, hGIIA-R7E/K10E/K16E, was secreted into the cul-
ture medium in the absence of high salt. When CHO-K1 cell
clones expressing hGX were treated as above, almost all of the
hGX, 97  5% (average of three experiments), was found in the
culture medium in the absence of high salt, as expected given
that this sPLA2 is a slightly acidic protein (calculated pI of 5.1).
hGIIA is known to bind tightly to heparin (35), a highly
anionic polymer. We measured the fraction of extracellular
hGIIA that could be captured in the culture medium in the
presence of heparin. hGIIA-transfected HEK293 cells (clone 1)
were first washed with culture medium without high salt to
remove hGIIA in the medium and then were cultured for 24 h
in the presence of various concentration of heparin added to the
culture medium. The amount of hGIIA enzymatic activity re-
leased into the medium was quantified by fluorimetric assay,
and the amount of remaining cell-associated hGIIA was quan-
tified in the same way after cells were further washed with
medium containing 1 M NaCl. The results in Fig. 1S (Supple-
mental Material) show that increasing heparin leads to a pro-
gressive increase in the amount of hGIIA in the culture me-
dium. A dose of 0.25–0.50 mg/ml heparin is sufficient to remove
the maximal amount of hGIIA from the cell surface (85%,
recall that 50% of the secreted enzyme is in the medium, in
the absence of heparin or high salt). Low molecular mass hep-
arin (3,000 Da) was less efficient at removing cell surface
hGIIA; 3–4 mg/ml was required to remove a maximal amount
of 85% of the hGIIA (not shown).
Glycosaminoglycan and GPI-linked Proteins Are Not Re-
quired for hGIIA- and hGX-dependent Arachidonate Re-
lease—We also expressed hGIIA and hGX in two CHO-K1
mutant cell lines. pgsA-745 cells have a defect in the glycosami-
noglycan biosynthetic pathway and contain no detectable
(5%) total glycosaminoglycan (as assessed by high pressure
liquid chromatography analysis of [35S]sulfate-labeled cells,
(36, 37)). GPI-LA1 cells are defective in the GPI biosynthetic
enzyme that N-deacetylates N-acetylglucosamine phospha-
tidylinositol (38). These cells lack GPI-linked proteins (based
on the absence of cell surface alkaline phosphatase and the
major GPI-linked protein GPI-130 (38)).
After screening for hGIIA expression (by enzymatic activity
measurement) in pgsA-745 and GPI-LA1 cells, three clones
from each group were submitted to [3H]arachidonate release
analysis in the presence and absence of FBS and IL-1. We
found no statistically significant difference in [3H]arachidonate
release from these mutant cells compared with hGIIA-trans-
fected wild type CHO-K1 clones (normalized for different
amounts of sPLA2 enzymatic activity measured in the high salt
wash of cells cultured for the same time period) (not shown).
There was also no statistically significant difference in the
amount of arachidonate liberated from nontransfected wild
type, pgsA-745, and GPI-LA1 CHO cells in response to FBS and
IL-1 (not shown). Finally, there was no statistically signifi-
cant difference in arachidonate release from hGX-transfected
wild type, pgsA-745, and GPI-LA1 clones (again after normal-
ization for sPLA2 enzymatic activity) (not shown). These re-
sults show that the amount of arachidonate liberated by hGIIA
and hGX in CHO-K1 cells is not altered by the absence of
glycosaminoglycan and GPI-link proteins.
We also examined the distribution of secreted hGIIA be-
tween the medium and the cell surface of pgsA-745 and GPI-
LA1 cells when washed cells were treated with medium con-
taining various concentrations of added NaCl (0.12–1 M). As
shown in Fig. 2S (Supplemental Material), the salt dependence
of the release of hGIIA from the cell surface was similar for wild
type and pgsA-745 cells, and release of hGIIA from GPI-LA1
cells required a slightly lower salt concentration. Approxi-
mately 0.2–0.25 M NaCl is required to release half as much
enzyme as that released with 1 M salt, and inclusion of concen-
trations of NaCl higher than 1 M would not be expected to
liberate more hGIIA. Although this data does not rule out the
binding of hGIIA to proteoglycan or a GPI-linked protein on the
surface of wild type CHO-K1 cells, it is clear that such compo-
nents are not obligatory for the association of secreted hGIIA
with the extracellular cell surface. The fact that heparin can
dissociate hGIIA from the cell surface does not establish that
this enzyme is bound to a glycosaminoglycan polymer on the
cell surface. Because hGIIA binds tightly to heparin, the pres-
ence of this anionic polymer in the culture medium can remove
cell surface hGIIA by mass action, regardless of the cell com-
ponent(s) to which the enzyme is bound, as long such cell
surface binding is not irreversible.
Arachidonate Release from CHO-K1 Cells Is Not Due to Ex-
tracellular hGIIA—To investigate whether hGIIA bound to the
extracellular face of the plasma membrane of CHO-K1 cells is
involved in arachidonate release, we measured the release of
[3H]arachidonate into the culture medium by hGIIA-trans-
fected CHO-K1 cells (clones 1 and 4) in the presence of suffi-
cient heparin to cause maximum release of hGIIA to the cul-
ture medium. As shown in Fig. 2, when hGIIA-transfected cells
were stimulated with FBS and IL-1, [3H]arachidonate re-
leased into the culture medium was enhanced compared with
nontransfected cells. Remarkably, when these experiments
were repeated in the presence of heparin (present during the
24-h period in which cells were labeled with [3H]arachidonate
and during the stimulation period), no inhibition of [3H]ara-
chidonate release was observed for both nontransfected and
hGIIA-transfected cells (Fig. 2). The concentration of heparin
used, 1 mg/ml, is more than sufficient to cause maximal release
of hGIIA into the culture medium (Fig. 1S). Use of 4 mg/ml
heparin resulted in a slight increase in released [3H]arachi-
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donate for both transfected and nontransfected cells (Fig. 2).
This lack of inhibition of [3H]arachidonate release by extracel-
lular heparin was observed in six independent experiments,
each done in triplicate, and maximal release of hGIIA enzy-
matic activity into the culture medium by heparin was con-
firmed by submitting the same culture medium used for scin-
tillation counting to the fluorimetric sPLA2 enzymatic assay.
These results, together with the fact that [3H]arachidonate
release in these cells is proportional to the amount of expressed
hGIIA (Fig. 1A), argue strongly that externalized hGIIA is not
responsible for [3H]arachidonate release. Strictly speaking, we
cannot rule out the possibility that the small amount of exter-
nalized hGIIA that may remain cell surface-bound in the pres-
ence of heparin is responsible for [3H]arachidonate release.
However, the studies described below with Me-Indoxam
strongly argue against this possibility.
The amount of [3H]arachidonate released from FBS/IL-1-
stimulated CHO-K1 cells expressing hGIIA-R7E/K10E/K16E
was not statistically different from that from cells expressing
similar levels of wild type hGIIA (not shown). This result,
together with the observation that essentially all of the mutant
enzyme accumulates in the culture medium, argues that cell
surface hGIIA is not responsible for the arachidonate release.
As shown in Fig. 3A, [3H]arachidonate release by hGIIA in
transfected CHO-K1 cells was completely insensitive to concen-
trations of Me-Indoxam that are more than sufficient to fully
block the enzymatic activity of hGIIA (1,000-fold the IC50
measured for inhibition of hGIIA by Me-Indoxam in an in vitro
assay (29)). We ruled out the trivial explanation that Me-
Indoxam was degraded in the cell culture well. Thus, Me-
Indoxam was added to complete culture medium above
CHO-K1 cells for 6 h. Dilution of an aliquot of this medium into
the fluorimetric hGIIA assay solution to give the IC50 concen-
tration of Me-Indoxam (previously determined for the Me2SO
stock solution of Me-Indoxam) produced 48% inhibition (no
FIG. 2. Effect of extracellular heparin on arachidonate release
by CHO-K1 cells transfected with hGIIA. hGIIA-transfected
CHO-K1 cells (clones 1 and 4) were culture for 24 h in the presence of
[3H]arachidonate and in the presence of the indicated amount of hepa-
rin. The cells were washed to remove unincorporated [3H]arachidonate
and then stimulated with FBS  IL-1 for 6 h in the presence of the
indicated amount of heparin in the medium. Release of [3H]arachido-
nate into the culture medium was measured as described under “Ex-
perimental Procedures.” Plotted is the difference in [3H]arachidonate
release (% of total) between stimulated ( FBS, IL-1) and nonstimu-
lated ( FBS,  IL-1) cells. The data shown are representative of two
independent experiments, each done in triplicate; the error bars show
the standard deviation from one of the triplicate analyses.
FIG. 3. Effect of Me-Indoxam on arachidonate release by
CHO-K1 cells transfected with hGIIA or hGX. A, hGIIA-trans-
fected CHO-K1 cells (clones 1 and 4) were stimulated for 6 h in the
presence of FBS and IL-1  and the indicated concentration of Me-
Indoxam (which was also present during the 24-h [3H]arachidonate
labeling period), and release of [3H]arachidonate into the culture me-
dium was measured as described under “Experimental Procedures.” B,
as for A but with hGX-transfected CHO-K1 cells (clones 5 and 6), and
stimulation with FBS and IL-1 was for 3 or 6 h as indicated. The data
on the right side of the figure is for nontransfected CHO-K1 cells treated
for 3 h with 100 ng/ml exogenously added recombinant hGX in the
presence of the indicated concentrations of Me-Indoxam. Plotted is the
difference in [3H]arachidonate release (% of total) between stimulated
( FBS,  IL-1) and nonstimulated ( FBS,  IL-1) cells. The data
shown are representative of two independent experiments, each done in
triplicate; the error bars show the standard deviation from one of the
triplicate analyses.
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inhibition was observed when medium lacking added Me-In-
doxam was substituted); thus, Me-Indoxam is completely sta-
ble under the conditions of Fig. 3A. A second hGIIA inhibitor
LY311727 (39), which is structurally related to Me-Indoxam,
also failed to inhibit arachidonate release in hGIIA-transfected
CHO-K1 cells when tested up to 50 M (not shown).
The studies described below conclusively show that Me-In-
doxam does not pass through the plasma membrane of mam-
malian cells. Thus, the lack of inhibition of hGIIA-dependent
arachidonate release in CHO-K1 cells by the extracellular,
cell-impermeable agents Me-Indoxam and heparin strongly ar-
gues that the free fatty acid is produced by enzyme before it is
secreted to the outside of the cell. It would be expected that
Me-Indoxam would inhibit arachidonate release by hGIIA
added exogenously to CHO-K1 cells. It was found that large
amounts of exogenously added hGIIA are needed to get detect-
able [3H]arachidonate release from CHO-K1 cells (see the In-
troduction). The addition of 15 g/ml hGIIA to CHO-K1 cells in
the presence of serum led to 4.8  0.3% [3H]arachidonate in
12 h, whereas the release was 3.8  0.3% in the absence of
added hGIIA. Co-addition of 10 M Me-Indoxam along with
hGIIA led to complete inhibition (3.6  0.2% measured
[3H]arachidonate release). This shows that exogenously added
hGIIA is accessible to Me-Indoxam and that the small amount
of [3H]arachidonate released over a prolonged period is due to
the action of hGIIA. It may also be noted that the addition of
recombinant hGIIA in the low g/ml range to some mammalian
cells and tissues such as guinea pig bronchoalveolar lavage
cells and lung pleural strips led to fatty acid release that was
completely blocked by submicromolar to low micromolar con-
centration of LY315920 (40), a compound very similar in struc-
ture to Me-Indoxam. We have shown previously that the addi-
tion of a tryptophan to the interfacial binding surface of hGIIA
dramatically promotes the binding of this enzyme to phosphati-
dylcholine rich vesicles in vitro and also allows the enzyme to
more efficiently act on the plasma membrane of mammalian
cells when added exogenously (23). As shown in Fig. 3S (Sup-
plemental Material), exogenous addition of the hGIIA-V3W
mutant (10 g/ml) leads to statistically significant release of
[3H]arachidonate into the culture medium (in just 4 h), and this
release is fully blocked by 1 and 10 M Me-Indoxam.
Arachidonate Release by hGX from CHO-K1 Cells Is Par-
tially Due to Extracellular Enzyme—We tested the ability of the
cell-impermeable inhibitor Me-Indoxam to block [3H]arachido-
nate release from CHO-K1 cells transfected with hGX (heparin
was not studied because hGX does not bind to heparin; how-
ever, see below). The results summarized in Fig. 3B show that
10 or 50 M Me-Indoxam has no effect on the amount of
[3H]arachidonate released into the culture medium when hGX-
transfected CHO-K1 cells (clones 5 and 6) were stimulated with
FBS and IL-1 for 3 h, but partial and dose-dependent inhibi-
tion is seen when released [3H]arachidonate is quantified after
6 h of stimulation. Me-Indoxam at 10 M blocks most of the
[3H]arachidonate released by exogenously added hGX, and the
inhibition is complete with 50 M compound (Fig. 3B). It is
remarkable that Me-Indoxam inhibits [3H]arachidonate by
hGX and not by hGIIA (see above) because this compound
inhibits hGIIA with an in vitro IC50 of 6–30 nM compared with
a value of 1–2 M for hGX (29).
Localization of hGIIA in CHO-K1 Cells by Immunofluores-
cence Confocal Microscopy—hGIIA-transfected CHO-K1 cells
were formaldehyde-fixed and permeabilized with Triton X-100,
and hGIIA was visualized by laser scanning confocal micros-
copy using a highly specific anti-hGIIA antiserum (2). The
results shown in Fig. 4 (A and C) show intense fluorescence
from regions that appear to be the Golgi based on positioning
near the nuclear envelope but not fully surrounding the nu-
clear envelope. This staining is similar to that seen for the
Golgi-specific marker NBD-C6-ceramide (Fig. 4H). Faint, per-
haps punctate staining is also seen in other regions of the cell,
but this was indistinguishable from the faint staining seen
with nontransfected cells (Fig. 4B). Stimulation of hGIIA-
transfected CHO-K1 cells with FBS and IL-1 for 5 h (Fig. 4D)
or treatment of the cells with heparin (Fig. 4E) did not change
the staining pattern. Also, hGIIA-transfected pgsA-745
CHO-K1 cells (Fig. 4F) and wild type CHO-K1 cells transfected
with the enzymatically deficient mutant hGIIA-H47Q (Fig. 4G)
showed similar staining as for hGIIA-transfected wild type
cells. Thus, the localization of hGIIA is tentatively assigned to
Golgi (confirmed by electron microscopy studies given below)
presumably as part of the classical secretory process.
Arachidonate Release in HEK293 Cells Transfected with
hGIIA and hGX—HEK293 clones stably transfected with
hGIIA and hGX were prepared and submitted to the same
arachidonate release assay as for the CHO-K1 cells. Fig. 5A
shows the amount of [3H]arachidonate released into the me-
dium (again expressed as a percentage of total [3H]arachido-
nate) from three different hGIIA-HEK293 clones in the pres-
ence and absence of FBS and with increasing amounts of IL-1.
As with CHO-K1 cell transfectants, hGIIA-transfected
FIG. 4. Confocal immunofluorescence microscopy of hGIIA-
transfected CHO-K1 cells. A, hGIIA-transfected wild type cells; B,
nontransfected wild type cells; C, hGIIA-transfected wild type cells; D,
hGIIA-transfected wild type cells stimulated for 5 h with FBS and IL1;
E, hGIIA-transfected wild type cells treated for 12 h with 4 mg/ml low
molecular mass heparin; F, hGIIA-transfected pgsA-745 cells; G,
hGIIA-H47Q-transfected wild type cells; H, wild type cells stained with
NBD-C6-ceramide. A and B are with a 20 objective, and C–H are with
a 60 objective.
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HEK293 cells show an increase in [3H]arachidonate in the
presence of FBS and a further increase when IL-1 is added.
Note that [3H]arachidonate release from nontransfected
HEK293 cells is enhanced 2-fold by FBS, no further increase
in fatty acid release occurs with IL-1, and release of [3H]arac-
hidonate in the presence of FBS is 3-fold less than from
nontransfected CHO-K1 cells in the presence of FBS and IL-1
(Fig. 1A). In hGIIA-transfected HEK293 cells, [3H]arachido-
nate release depends on the dose of IL-1, with half-maximal
fatty acid release occurring with 0.05 ng/ml for all three
transfected clones. Despite this common dose response, the
different clones show different maximal responsiveness to IL-
1. Clones 1 and 3 both show an 6-fold increase in [3H]arac-
hidonate release in response to FBS alone, but clone 1 shows a
3-fold maximal increase in [3H]arachidonate in response to
IL-1, whereas only a 1.5-fold increase is seen for clone 3.
Clone 4 shows a smaller response to FBS, 3-fold increase in
[3H]arachidonate, and a further increase in fatty acid release
caused by IL-1 reaches 1.5-fold. These results in Fig. 5A
were reproducible after five independent experiments, each
done in triplicate. The amount of FBS-induced [3H]arachido-
nate release from the three hGIIA-transfected HEK293 cell
clones correlates with the amount of hGIIA protein being ex-
pressed (as measured by enzymatic activity assay; inset of Fig.
5A). Finally, [3H]arachidonate release from these clones was
time-dependent over 0–6 h (not shown).
It is possible that albumin present in FBS is responsible for
the increase in [3H]arachidonate release when cells are stimu-
lated with medium containing 10% FBS compared with serum-
free medium (also for the IL-1-dependent increase because
the commercial preparation of this cytokine contains small
amounts of albumin) because albumin serves as an extracellu-
lar sink for free fatty acids. However, this is not the case
because the addition of 0.5% BSA to serum-free medium in the
presence or absence of IL-1 does not alter the amount of
[3H]arachidonate release from hGIIA- and hGX-transfected
HEK293 (not shown). Thus, it appears that IL-1 alone and
factor(s) in FBS other than albumin are able to stimulate fatty
acid release from these cells.
As for CHO-K1 cells, we quantified the amount of tritium in
the neutral lipid fraction obtained by organic solvent extraction
of the HEK293 cell pellets. Nontransfected HEK293 cells were
found to contain 0.8  0.1% of the total radiolabel in the
neutral lipid fraction, and this number did not change, 0.7 
0.1%, when cells were stimulated with FBS/IL-1. For hGIIA-
transfected HEK293 cells clones 1, 3, and 4, 1.0  0.1, 0.9 
0.1, and 1.0  0.2%, respectively, of the total tritium was found
in the neutral lipid fraction derived from the cell pellets, and
the corresponding numbers after FBS/IL-1 stimulation were
1.0  0.1, 1.1  0.2, and 0.9  0.1%, respectively, for the three
different clones. Thus, as for CHO-K1 cells, essentially all of
the increase in [3H]arachidonate resulting from transfecting
cells with hGIIA is released to the culture medium.
Fig. 5B shows similar experiments carried out with hGX-
transfected HEK293 cells. As for hGIIA-transfected cells, FBS
causes an increase in [3H]arachidonate release in hGX-trans-
fected cells. Interestingly, hGX-HEK293 clone 3 shows no ad-
ditional release in [3H]arachidonate in the presence of IL-1. In
contrast, IL-1, in a dose-dependent fashion, enhances
[3H]arachidonate from hGX-HEK293 clones 1 and 2, with a
maximal increase of 2-fold in both cases. [3H]Arachidonate
release was time-dependent over 0–6 h (not shown). The
amount of [3H]arachidonate released from the three hGX-
transfected HEK293 cell clones is correlated with the amount
of hGX that they expressed as determined by enzymatic activ-
ity assay (inset of Fig. 5B).
Secreted hGIIA but Not hGX Is Bound to the Cell Surface of
HEK293 Cells—hGIIA-transfected HEK293 cells (clone 1) were
washed with complete medium and then covered with complete
medium containing 4 ng/ml IL-1 and various concentrations
of heparin. After 6 h at 37 °C, the medium was removed, and
the cells were treated with complete medium containing 1 M
NaCl for 15 min at 37 °C. The results are shown in Fig. 4S
(Supplemental Material). In the absence of heparin, it was
found that 3-fold more enzyme activity was found in the high
salt wash compared with medium in which NaCl was not
added, indicating that approximately 75% of the secreted
hGIIA is cell surface-bound (assuming that the salt removes all
of the bound enzyme). Extracellular heparin allows transfer of
hGIIA to the medium, with less than 0.25 mg/ml heparin
being required to cause 50% of the maximal effect (Fig. 4S); 1
FIG. 5. Arachidonate release by HEK293 cells transfected with
hGIIA (A) or hGX (B). Arachidonate release is expressed as a percent-
age of total [3H]arachidonate (medium  cell associated) released into
the medium after 4 h of culture in the presence and absence of FBS and
IL-1 (0–2 ng/ml) as indicated. The data for nontransfected and three
different transfected clones are shown. The inset shows the amount of
sPLA2 secreted from the transfected cells (quantified by the fluorimetric
enzymatic assay). The data shown are representative of five independ-
ent experiments, each done in triplicate; the error bars show the stand-
ard deviation from one of the triplicate analyses.
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mg/ml heparin removes 90% of the secreted hGIIA from the
cell surface. Essentially identical results were obtained with a
different hGIIA-HEK293 clone (clone 3; not shown). The
amount of hGIIA enzymatic activity secreted into the culture
medium in the presence or absence of heparin did not depend
on the presence of IL-1 (not shown), suggesting that this
cytokine does not modulate the amount of enzyme secreted
from cells.
In the case of hGX-transfected HEK293 cells, enzymatic
activity was detected in medium without added salt but not in
the high salt wash (not shown). Furthermore, the amount of
hGX activity in the medium was not influenced by the presence
of heparin. Thus, as in the case of CHO-K1 cells, essentially all
of the hGX is released into the culture medium. As for hGIIA-
transfected cells, IL-1 did not alter the amount of hGX enzy-
matic activity secreted from cells (not shown).
Arachidonate Release from HEK293 Cells Is Not Due to Ex-
tracellular hGIIA and hGX—To investigate whether [3H]arac-
hidonate release from HEK293 cells transfected with hGIIA or
hGX is due to extracellular enzyme, we carried out a series of
experiments analogous to those performed with transfected
CHO-K1 cells. We first tested whether exogenously added
hGIIA and hGX could release [3H]arachidonate from nontrans-
fected HEK293 cells. We have reported previously that release
of [3H]arachidonate into the medium is not detected when
HEK293 cells are treated with exogenous 1 g/ml hGIIA,
whereas even 10 ng/ml amounts of hGX gives detectable re-
lease (29). This was investigated in more detail in the present
study. As shown in Fig. 5S (Supplemental Material), no addi-
tional release of [3H]arachidonate into the medium above that
seen in the absence of added hGIIA was detected when non-
transfected HEK293 cells were pretreated with 10 g/ml hGIIA
for 6 h in the absence of IL-1 or when cells were treated with
IL-1 for 15 h followed by incubation with IL-1 and 10 g/ml
hGIIA for an additional 6 h. In addition, when the cell pellets
were extracted with chloroform/methanol and [3H]arachido-
nate was quantified after purification on a silica gel plate, only
a small amount of radiolabeled fatty acid was detected com-
pared with that released into the culture medium regardless of
whether cells were treated with hGIIA in the presence or
absence of IL-1 (Fig. 5S). When HEK293 cells were incubated
with hGIIA in complete medium for 6 h at 37 °C, 25–30% of the
added enzyme could be recovered based on enzymatic assay of
a small aliquot of culture medium using the fluorimetric assay.
Although some enzyme is lost, presumably because of binding
to the cell surface and/or the walls of the culture well, this
cannot be the reason that exogenously added hGIIA fails to
release [3H]arachidonate from HEK293 cells. On the other
hand, as shown in Fig. 5S, significant release of [3H]arachido-
nate into the medium was detected when HEK293 cells were
treated for 6 h with small amounts of recombinant hGX (100
ng/ml). Fatty release was perhaps slightly enhanced when
IL-1 was also present during the period of treatment with
hGX.
As show in Fig. 3S (right side), detectable [3H]arachidonate
release was observed when 10 g/ml hGIIA-V3W was added to
nontransfected HEK293 cells (as for CHO-K1 cells). The addi-
tion of 1 and 10 M Me-Indoxam to the culture medium leads to
complete inhibition of [3H]arachidonate release from nontrans-
fected HEK293 cells treated with exogenous hGIIA-V3W (as for
CHO-K1 cells). These results with exogenous hGIIA-V3W and
hGX (see above) argue that the period of labeling of cells with
[3H]arachidonate (20–24 h) is sufficient to allow those phos-
pholipids that are exposed to exogenous sPLA2s to become
radiolabeled. Furthermore, if nontransfected HEK293 cells
were labeled with [3H]arachidonate for an even longer period
(36 h), no measurable [3H]arachidonate release into the me-
dium was observed when cells were treated with 10 g/ml wild
type hGIIA for 6 h, regardless of whether cells were pretreated
with 2 ng/ml IL-1 for 16 h prior to the addition of the sPLA2.
Fatty acid release was readily detected when cells were treated
for 6 h with 100 ng/ml hGX (not shown).
As shown in Fig. 6S (Supplemental Material), as expected,
the amount of hGIIA in the culture medium depends on the
length of time that hGIIA-transfected HEK293 cells were cul-
tured. When HEK293 cells are cultured in complete medium
for 15 h, the amount of enzyme in the culture medium is
4-fold higher than the amount secreted after the cells are
washed to remove accumulated extracellular hGIIA and then
cultured for an additional 6 h. The same is true when heparin
is present in the culture medium either during the first 15-h
period or the second 6-h period except that the amount of
released hGIIA is much larger than when heparin is not pres-
ent as expected (Fig. 6S). Thus, these cells continuously pro-
duce extracellular hGIIA over the combined 21-h period, and
this hGIIA is continuously trapped in the culture medium by
the presence of heparin.
Next we studied the effect of heparin on [3H]arachidonate
release from HEK293 cells transfected with hGIIA. The cells
were labeled with [3H]arachidonic acid for 15 h in the presence
of FBS, washed, and then stimulated for 6 h in the presence of
FBS and in the presence or absence of IL-1. Heparin was
present only during the 15-h period, only during the 6-h period,
during both periods, or not present at all. Only the [3H]arachi-
donate released during the 6-h period was measured. The re-
sults are shown in Fig. 7SA for clone 1 and in Fig. 7SB for clone
3 (Supplemental Material). Heparin shows a complex effect.
When it is present only during the 15-h labeling period, it
causes a slight increase in [3H]arachidonate release compared
with the no heparin control. On the other hand, when heparin
is present only during the 6-h stimulation period, it causes
partial inhibition of [3H]arachidonate release. When heparin is
present all the time (15  6 h), inhibition of [3H]arachidonate
release is observed and to a similar degree as the inhibition
seen when heparin is present only during the 6-h stimulation
period. Inhibition of [3H]arachidonate release by heparin is
seen both in the presence and absence of IL-1. Finally, the
degree of inhibition of [3H]arachidonate release by heparin
depends on the transfected HEK293 clone. For clone 1, heparin
inhibition is approximately 60% (Fig. 7SA), whereas for clone 3
it is only approximately 20% (Fig. 7SB).
We also studied the effect of heparin on [3H]arachidonate
release from HEK293 cells transfected with hGX, and the re-
sults are summarized in Fig. 8SA for clone 2 (IL-1-sensitive)
and in Fig. 8SB for clone 3 (IL-1-insensitive) (Supplemental
Material). The results are similar to those obtained with
hGIIA-transfected HEK293 cells (Figs. 7SA and 7SB). Heparin
causes a slight activation in [3H]arachidonate released when it
is present during the 15-h labeling period and causes partial
inhibition when present during the 6-h stimulation period or
when present all the time (21 h). These results with heparin for
hGIIA and hGX-transfected HEK293 cells (Figs. 7S and 8S)
were reproducible after three independent experiments, each
done in triplicate.
We tested Me-Indoxam for its ability to inhibit [3H]arachi-
donate release from hGIIA-transfected HEK293 cells. It is clear
from the results in Fig. 6A that 0.5–10 M Me-Indoxam has no
effect on the amount of [3H]arachidonate released into the
medium from cells stimulated with FBS/IL-1. This is true for
clone 1 (Fig. 6A) and clone 3 (not shown), which are responsive
to IL-1, and with clone 4, which is less responsive to cytokine
(not shown). In addition, 50 M LY311727 did not reduce
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[3H]arachidonate release (not shown). For all three HEK293-
hGIIA clones, there was also no effect of 0.1–10 M Me-In-
doxam on [3H]arachidonate release induced by serum in the
absence of IL-1 (not shown). Similarly, as shown in Fig. 6B,
0.5–10 M Me-Indoxam has no effect on the amount of [3H]arac-
hidonate released into the medium from hGX-transfected HEK
cells stimulated with serum and IL-1 (clones 2 and 3) or
serum alone (not shown). Also, no inhibition of [3H]arachido-
nate from hGIIA- and hGX-transfected cells was seen when 10
M Me-Indoxam was included throughout the period in which
cells were labeled with [3H]arachidonate and during the stim-
ulation period (not shown).
We used two different methods to gauge the ability of Me-
Indoxam to enter the cytosol of mammalian cells. In one assay,
nontransfected HEK293 cells were incubated with [3H]Me-In-
doxam for 20 min at 37 °C, and the cells were rapidly separated
from the culture medium by centrifugation through a layer of
100% FBS (33). The well established cell-impermeable com-
pound 1-[3H]-D-mannitol was used as a negative control, and
the well established cell permeable compound 4-[3H]-L-pro-
pranolol was used as a positive control. The results in Fig. 9S
(Supplemental Material) show that the amounts of 1-[3H]-D-
mannitol and [3H]Me-Indoxam that reach the bottom of the
centrifuge tube is independent of the number of HEK293 cells
in the incubation. Fig. 9S also shows the expected behavior if
the intracellular concentration of [3H]Me-Indoxam reaches the
extracellular concentration of 5 M. This curve was calculated
assuming a cell radius of 10 microns. In contrast, the amount of
4-[3H]-L-propranolol to reach the tube bottom is proportional to
the cell number, as expected for this readily cell-permeable
compound. The data argue that the radius of these HEK293
cells is larger than 10 microns. Thus, it is clear that Me-
Indoxam, like mannitol, fails to enter the cytosol of HEK293
cells. [3H]Me-Indoxam almost certainly partitions into the ex-
tracellular leaflet of the plasma membrane, and thus some
compound might have been expected to pellet with the cells at
the bottom of the centrifuge tube. However, the derivation
given as Supplemental Material shows that membrane-bound
[3H]Me-Indoxam is expected to dissociate into the extracellular
medium with a half-life on the order of 1 s. Thus, all of the
outer membrane leaflet compound is expected to desorb from
the cell membranes during the time that it takes for the cells to
pass through the serum layer, where the concentration of free
[3H]Me-Indoxam is close to 0.
We also examined the cell permeability of Me-Indoxam using
the well established Caco-2 cell monolayer assay. These cells
are derived from the human gut epithelium and from tight
intercellular junctions that are essentially impermeable to wa-
ter-soluble low and high molecular mass compounds. Measure-
ments were made in both the apical-to-basolateral (AB) direc-
tion and in the reverse direction (BA) because it is well
established that transporters and pumps can modulate the
passage of compounds across the Caco-2 cell monolayer. In this
assay Me-Indoxam had very low apparent permeability values
(Papp) of 0.08 and 0.1  10
6 cm/s (duplicate runs in the AB
direction) and 0.20 and 0.17  106 cm/s in the BA direction.
These values are comparable with those measured for manni-
tol, 0.1–0.2 106 cm/s, which cannot cross the cell membrane
either passively or actively and is thought to slowly leak
through the tight junctions between adjacent cells. In contrast,
propranolol is thought to rapidly cross the cell membrane by
passive diffusion and gave Papp values of 53.6 and 52.5  10
6
cm/s (AB) and 29.8  106 cm/s (BA). Vinblastine is a well
established substrate for P-glycoprotein that actively trans-
ports compounds in the BA direction. This compound gave
values of Papp of 1.87 and 2.2  10
6 cm/s (AB) and 47.6 and
39.5  106 cm/s (BA). Ranitidine is considered a poorly per-
meable standard and gave Papp values of 0.84 and 0.90  10
6
cm/s (AB) and 3.5 and 3.1  106 cm/s (BA). The recovery of all
compounds was79% (obtained from the concentrations of test
compound measured on both the donor and acceptor sides of
the cell monolayer). Additional information about the Caco-2
assay is given as Supplemental Material. These data showing
essentially no passage of Me-Indoxam across the caco-2 cell
monolayer other than transfer between cells are consistent
with the HEK293 cell uptake studies measured by the centrif-
ugation method.
Localization of hGIIA in HEK293 Cells by Immunofluores-
cence-Confocal and Immunogold Electron Microscopies—We
FIG. 6. [3H]Arachidonic acid release from HEK293 cells in the
presence of sPLA2 inhibitors. A, HEK293-hGIIA cells (clone 1) in the
presence and absence of FBS, IL-1, and inhibitor (Inh.) as noted.
Me-Indoxam was used at 0–10 M, as noted; the last bar is with 50 M
LY311727. B, same as for A except with HEK293-hGX cells (clones 2
and 3). The data shown are representative of five independent experi-
ments, each done in triplicate; the error bars show the standard devi-
ation from one of the triplicate analyses. See text for additional
information.
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studied the localization of hGIIA in transfected HEK293 cells
by immunofluorescence confocal microscopy, and the results
are shown in Fig. 7. When the cells were fixed with formalde-
hyde (at room temperature) and permeabilized with Triton
X-100 (same conditions as used for CHO-K1 cells; Fig. 4),
hGIIA localized to a region tentatively assigned to the Golgi
compartment. When the cells were fixed with formaldehyde (at
room temperature or 4 °C) and permeabilized with 1% saponin
(conditions reported previously (21)), hGIIA was detected
throughout the cytosol (Fig. 7, C and D) with some punctate
staining appearing in Fig. 7D. Similar diffuse-type cytosolic
staining was seen with hGIIA-transfected CHO-K1 cells per-
meabilized with 1% saponin (not shown). This diffuse staining
is probably the result of the relatively high amount of saponin
used; most studies use 0.1% saponin.
We also investigated the intracellular distribution of hGIIA
at the electron microscopic level by preparing ultra thin sec-
tions of hGIIA-transfected HEK293 cells (clone 1) and labeling
with a hGIIA-specific antibody. The intracellular distribution
of hGIIA in HEK293 treated with serum or with serum and
IL-1 and in the absence and presence of extracellular heparin
was similar (Fig. 8). Intracellular labeling was confined to the
Golgi complex (Fig. 8, A and B). hGIIA labeling was also seen
on the cell surface (Fig. 8C). Although the labeling density was
low, detailed examination of the labeled sections revealed only
sparse background labeling elsewhere, and this labeling was
indistinguishable from the labeling of the nontransfected cells.
Caveolae, identified by labeling for caveolin-1, were rare in
HEK293 cells but generally showed negligible labeling for
hGIIA in double labeled sections (Fig. 8D).
Involvement of cPLA2- in arachidonate release in hGIIA and
hGX-transfected HEK293 and CHO-K1 cells—We tested two
structurally distinct, potent, and selective inhibitors of
cPLA2-, pyrrophenone (27, 41) and AZ-1 (compound 22 in Ref.
28), for their possible effect on [3H]arachidonate release from
hGIIA- and hGX-transfected HEK293 cells. As shown in Fig.
9A, [3H]arachidonate release from nontransfected cells is in-
sensitive to IL-1 (consistent with the results in Fig. 5A) or to
the addition of pyrrophenone or AZ-1. In hGIIA-transfected
HEK293 cells clone-1 (which is highly sensitive to IL-1; Fig.
5A), in the absence of IL-1, [3H]arachidonate release is 2-
fold higher than in nontransfected cells, and pyrrophenone
blocks approximately 50% of this increase. The degree of inhi-
bition by pyrrophenone is the same at all three doses (0.2, 2,
and 10 M), suggesting that pyrrophenone is inhibiting all of
the cPLA2-. The addition of IL-1 to clone 1 approximately
doubles the amount of [3H]arachidonate release, and all three
doses of pyrrophenone dramatically reduce [3H]arachidonate
release, bringing it close to the level seen in the presence of
pyrrophenone and in the absence of IL-1 (Fig. 9). The second
cPLA2- inhibitor AZ-1 also causes substantial inhibition of
[3H]arachidonate release but is less potent than pyrrophenone
(Fig. 9A). With hGIIA-transfected HEK293 cells (clone 4),
which show a smaller response than clone 1 to IL-1 (Fig. 8A),
the two cPLA2- inhibitors cause a similar response as seen
with clone 1 (Fig. 9A).
As shown in Fig. 9B, addition of the cPLA2- inhibitors to the
IL-1-responsive hGX-transfected HEK293 cell clone 2 blocked
all of the additional [3H]arachidonate release induced by IL-1.
As noted earlier, [3H]arachidonate release in the absence of
IL-1 was larger than in hGIIA-transfected HEK293 cells, and
this was completely insensitive to the cPLA2- inhibitors.
[3H]Arachidonate release from hGX-transfected HEK293 cells
clone 1, which is much less sensitive to IL-1 (Fig. 5B), is
virtually insensitive to the cPLA2- inhibitors (Fig. 9B).
As shown in Fig. 10S, HEK293 cells express cPLA2- as
detected by immunoblot analysis. The level of cPLA2- does not
seem to vary between nontransfected cells and those trans-
fected with hGIIA (clones 1 and 4) or hGX (clones 2 and 3).
We also studied the effect of pyrrolidine-1, an analog of
pyrrophenone that is also a potent inhibitor of cPLA2- (27, 42),
on [3H]arachidonate release from hGIIA-transfected CHO-K1
cells. Nontransfected cells released 3.8  0.2% more [3H]ara-
FIG. 7. Confocal immunofluorescence microscopy of hGIIA-
transfected HEK293 cells. A, hGIIA-transfected HEK293 cells fixed
at room temperature and permeabilized with Triton X-100 at room
temperature; B, nontransfected HEK293 cells prepared as in A; C,
hGIIA-transfected HEK293 cells fixed at 4 °C and permeabilized with
1% saponin at room temperature; D, same as C but fixed at room
temperature.
FIG. 8. Immunoelectron microscopic location of hGIIA in
HEK293 cells. HEK293 cell lines expressing hGIIA PLA2 were either
untreated (A and D) or treated with IL-1 alone (B) or IL-1 and
heparin (C). They were then fixed in paraformaldehyde and processed
for frozen sectioning. Ultra thin sections were immunolabeled with
antibodies to hGIIA followed by 10-nm protein A gold. Specific labeling
(arrowheads) in all treatments was associated with the Golgi stack (G)
and associated membranes (A and B). Specific but variable labeling was
observed close to the plasma membrane (pm) (C). In addition, ultra thin
sections were immunolabeled with antibodies to hGIIA followed by
5-nm protein A gold, fixed, and then immunolabeled with antibodies to
caveolin 1 followed by 10-nm protein A gold (D). Caveolin-1 antibodies
labeled surface caveolae (arrowheads; inset shows higher magnification
view of one caveola), but negligible labeling for hGIIA (small arrow-
head) was observed in these structures. Bars, 200 nm.
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chidonate in the presence of serum and IL-1 compared with
nonstimulated cells, and this difference was reduced to 2.2 
0.1% in the presence of 5 M pyrrolidine-1. hGIIA-transfected
CHO-K1 cells (clone 4) showed a 4.8  0.2% difference in
[3H]arachidonate release between stimulated versus nonstimu-
lated cells and this difference was reduced to 2.4  0.2% in the
presence of 5 M pyrrolidine-1. Thus, approximately 50% of the
[3H]arachidonate from nontransfected cells appears to be due
to cPLA2-, which is consistent with the fact that these cells
were shown by immunoblot analysis to contain cPLA2- (43).
Inhibition of cPLA2- reduces most of the increase in [
3H]ara-
chidonate release induced by transfection of cells with hGIIA
(as for HEK293 cells).
DISCUSSION
[3H]Arachidonate Release by sPLA2s Prior to Enzyme Secre-
tion—It has already been noted that exogenously added hGIIA
is several orders of magnitude less efficient at liberating
arachidonic acid from HEK293 cells compared with cells con-
stitutively expressing this enzyme by stable transfection. The
simplest explanation for this result is that arachidonate re-
lease occurs by hGIIA prior to secretion to the extracellular
medium. It has been recently reported that exogenously added
hGIIA is internalized into HEK293 cells only when IL-1 is
added as shown by immunoblot analysis of cell pellet associ-
ated hGIIA only in the presence of cytokine (7). We did not
directly study the reinternalization of hGIIA into HEK293
cells, but it is clear from the results in Fig. 5S that the addition
of relatively large amounts of exogenous hGIIA to HEK293
cells in the presence or absence of pretreatment with IL-1
failed to produce detectable [3H]arachidonate release either to
the medium or as cell-associated free fatty acid. Perhaps some
[3H]arachidonate is released but is not detected because of
rapid reincorporation into phospholipid. However, the release
of [3H]arachidonate to the culture medium is readily detected
in hGIIA-transfected cells (Fig. 5A). Thus, it is suggested that
the [3H]arachidonate released from transfected cells is not due
to reinternalization of secreted hGIIA.
Additional strong evidence for this latter statement comes
from studies with Me-Indoxam. It is clear that the addition of
this sPLA2 inhibitor to hGIIA-transfected HEK293 and
CHO-K1 cells has no effect on [3H]arachidonate release. Con-
trol studies clearly show that Me-Indoxam is not destroyed by
cell-conditioned medium, and this compound blocks all of the
[3H]arachidonate release induced by exogenously added
sPLA2s (small amounts of hGX, enormous amounts of exog-
enously added hGIIA, and lower amounts of the hGIIA-V3W
mutant). By two independent assays, it is shown that Me-
Indoxam does not cross the plasma membrane of cells. The
glypican-shuttling mechanism or any other secretion followed
by re-entry mechanism for hGIIA action requires that the
sPLA2 comes in contact with the extracellular fluid. This would
allow hGIIA to bind Me-Indoxam even though this compound
cannot cross the plasma membrane. Thus, the complete lack of
inhibition by Me-Indoxam rules out mechanisms in which
[3H]arachidonate release is by hGIIA acting on the extracellu-
lar face of the plasma membrane or within an intracellular
vesicle compartment whose aqueous lumen is derived from the
extracellular medium. Me-Indoxam did not reduce [3H]arachi-
donate release even when it was included in the culture during
the several hour fatty acid labeling period. If secreted enzyme
produced during the labeling period is reinternalized and con-
tributes to [3H]arachidonate release during the stimulation
period, it should have been blocked by Me-Indoxam. In a pre-
vious study, it was reported that 10 M LY311727 (an sPLA2
inhibitor structurally related to Me-Indoxam but less potent on
hGIIA) partially inhibits [3H]arachidonate release from serum/
IL-1-stimulated, hGIIA-transfected HEK293 cells (19). In our
hands, even 50 M LY311727 fails to produce detectable inhi-
bition of hGIIA-transfected CHO-K1 and HEK293 cells when
examined in more than 10 experiments by two laboratory
workers.
We have confirmed the previous findings (19) that extracel-
lular heparin traps secreted hGIIA in the culture medium by
preventing its association with the surface of CHO-K1 cells
(Fig. 1S) and of HEK293 cells (Figs. 4S and 6S). Inhibition of
[3H]arachidonate release by extracellular heparin would argue
in favor of the re-entry model for action of this sPLA2 in
transfected cells. Extracellular heparin has no effect on
[3H]arachidonate release by hGIIA-transfected CHO-K1 cells
FIG. 9. Effect of cPLA2- inhibitors on arachidonate release by
HEK293 cells transfected with hGIIA (A) or hGX (B). Arachido-
nate release after 4 h of culture in the presence and absence of IL-1 (2
ng/ml) and in the presence or absence of the cPLA2- inhibitors pyrro-
phenone (Pyro) or AZ-1 as indicated (concentrations given along the x
axis). A shows data for nontransfected cells and for HEK293 cells
transfected with hGIIA (clones 1 and 4). B shows data for nontrans-
fected cells and for HEK293 cells transfected with hGX (clones 1 and 2).
Serum was present in all experiments. The data shown are represent-
ative of three independent experiments, each done in triplicate; the
error bars show the standard deviation from one of the triplicate
analyses.
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(Fig. 2), consistent with fatty acid release occurring prior to
exposure of hGIIA to the extracellular fluid. The effect of hep-
arin with HEK293 cells is complex. Although inhibition of
[3H]arachidonate release by extracellular heparin was ob-
served with hGIIA-transfected HEK293 cells (Fig. 7S, A and B)
several features strongly argue that this is not the result of
trapping of hGIIA. Firstly, removal of the majority of the se-
creted hGIIA by pretreatment of cells with heparin for 15 h has
no effect on the level of [3H]arachidonate released during the
subsequent 6-h period in which cells were stimulated with
serum and IL-1. If [3H]arachidonate release occurred by
hGIIA shuttled intracellularly from the cell surface, the
amount of fatty acid release during the 6-h stimulation period
should be less if there is less sPLA2 on the cell surface. Sec-
ondly, inhibition by extracellular heparin was partial (only
20% for hGIIA-HEK293) despite the fact that sufficient hep-
arin was added to fully remove hGIIA from the cell surface.
Thirdly, and perhaps most significantly, is the observation that
heparin also partially inhibited [3H]arachidonate release by
hGX-transfected HEK293 cells (Fig. 8S, A and B) despite the
fact that this sPLA2 has no detectable affinity for heparin (8).
Thus, the presence of extracellular heparin somehow reduces
[3H]arachidonate release following stimulation with serum and
IL-1 by a nonspecific mechanism, the details of which are not
understood. Thus, caution is advised in the use of extracellular
heparin, a highly anionic and polymeric substance, to explore
the mode of action of sPLA2s.
hGIIA has been localized to punctate domains throughout
the cytosol of transfected HEK293 cells, when studied by im-
munofluorescence-confocal microscopy using 1% saponin to
permeabilize the cells (21). It was suggested that these punc-
tate domains are caveolae or caveolae-derived vesicle compart-
ments based on co-location of hGIIA with caveolin-2. Although
we could see staining of hGIIA throughout the cytosol with
some punctate appearance in transfected HEK293 cells perme-
abilized with 1% saponin (Fig. 7), hGIIA appears to reside in
the Golgi compartment when cells were permeabilized with
0.2% Triton X-100 in both HEK293 (Fig. 7) and CHO-K1 cells
(Fig. 4). Furthermore, there was no effect of extracellular hep-
arin on the microscopic images. It should be pointed out that
caveolin-1 is considered to be a reliable marker of caveolae, but
caveolin-2 is more of a Golgi marker than a marker of caveolae
(see for example Refs. 44–48). Some caveolin-2 is found in
caveolae, in association with caveolin-1, but even in these
cases, most of the caveolin-2 detected by immunofluorescence
resides in the Golgi complex (45–47). A recent study showed
co-localization of human group V sPLA2 with caveolin-2 in
punctate domains in the macrophage-like cell line p388D1 (49).
Given the above concerns, the localization of human group V
sPLA2 in caveolae is called into question. Treatment of cells
with extracellular heparin reduces the amount of immunoflu-
orescence staining of hGIIA and group V sPLA2 in punctate
domains (21, 49), and this is cited as evidence that the punctate
localization of sPLA2 derives from re-entry of extracellular
enzyme. It may be noted that heparin treatment did not elim-
inate punctate staining (49). Furthermore, because heparin
forms high molecular mass, multi-protein/polymer aggregates
with basic sPLA2s (50), it is possible that the effect of heparin
is to prevent the transfer of extracellular sPLA2 into detergent-
permeabilized cells, given that formaldehyde fixation is typi-
cally not a complete process. In this context, we have found that
intracellular hGIIA staining is seen when CHO-K1 and
HEK293 cells are treated first with exogenous hGIIA followed
by formaldehyde fixation and detergent permeabilization and
that such intracellular staining is prevented by treating the
cells with extracellular heparin (not shown).
To further explore the localization of hGIIA in transfected
HEK293 cells, we turned to immunogold electron microscopy
using ultra thin sections. The results in Fig. 8 show that these
cells contain caveolae; however, we see localization of hGIIA
only at the cell surface and Golgi stacks. Although this is a
negative result for localization of hGIIA in caveolae, the elec-
tron microscopic images fit well with the overwhelming amount
of additional data in this study, ruling out the re-entry model
for hGIIA action in HEK293 and CHO-K1 cells.
Although we did not study the role of glypican, a GPI-an-
chored, heparan sulfate-containing proteoglycan, in promoting
[3H]arachidonate release in hGIIA-transfected HEK293 cells,
the observation that fatty acid release is fully intact in mutant
CHO-K1 cells that lack all glycosaminoglycans and GPI an-
chors establishes that glypican shuttling is not essential for
function of hGIIA in CHO-K1 cells.
The addition of Me-Indoxam has no effect on [3H]arachido-
nate released early from hGX-transfected CHO-K1 cells, but
this sPLA2 inhibitor partially blocks fatty acid released later in
time (Fig. 3B). The simplest explanation for this unusual be-
havior is that hGX-catalyzed [3H]arachidonate release occurs
in part by enzyme in the secretory compartment prior to exter-
nalization of enzyme, and a portion occurs by extracellular
enzyme acting on the extracellular face of the plasma mem-
brane. As time goes on, the extracellular concentration of hGX
rises (the amount of secreted hGX, detected with the fluorimet-
ric assay, increases linearly over the 0–24-h time period) until
it is high enough to lead to fatty acid release from the plasma
membrane. The latter process depends on the extracellular
concentration of enzyme; mass action dictates that dilution of
hGX by extracellular medium reduces the fraction of enzyme
bound to the plasma membrane. In contrast, the concentration
of membrane “seen” by hGX residing inside secretory compart-
ments is independent of the volume of culture medium, and
thus fatty acid release by hGX prior to secretion occurs at all
time points. With hGX-transfected HEK293 cells, Me-Indoxam
has no effect on [3H]arachidonate release, arguing that the
extracellular concentration of this sPLA2 never builds to a high
enough level to allow plasma membrane phospholipid hydrol-
ysis. In the case of hGIIA, which binds orders of magnitude
more weakly than hGX to the phosphatidylcholine-rich outer
plasma membrane (8, 23), [3H]arachidonate release occurs in
CHO-K1 and HEK293 cells only prior to enzyme secretion. This
model nicely explains why exogenously added hGIIA is orders
of magnitude less efficient at phospholipid hydrolysis than
hGIIA produced by transcription/translation within the cell;
the concentration of membrane that hGIIA “sees” is orders of
magnitude higher when enzyme is in the secretory compart-
ment compared with the extracellular medium. In vitro kinetic
studies show that hGX is orders of magnitude more active than
hGIIA on phosphatidylcholine-rich because only the former
enzyme can binding tightly to such vesicles (8, 23, 29). Thus,
one might anticipate that the intracellular membrane in which
the sPLA2 acts is rich in phosphatidylcholine based on the
observation that hGX is more efficient than hGIIA at liberating
[3H]arachidonate from transfected CHO-K1 and HEK293 cells
despite the fact that the specific activity of hGX is approxi-
mately 10-fold lower than that of hGIIA when both are tested
on their most preferred substrate (29).
Role of cPLA2- in IL-1-dependent [
3H]Arachidonate Re-
lease and Cross-talk between cPLA2- and sPLA2—We have
confirmed the previous observations that serum and IL-1
enhance [3H]arachidonate release in hGIIA-transfected
CHO-K1 and HEK293 cells (19). Early studies showed that
serum but not IL-1 enhances [3H]arachidonate release in
hGX-transfected HEK293 cells (18). This leads to the hypoth-
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esis that the IL-1 enhancement of fatty acid release and
glypican shuttling are somehow linked. However, in the pres-
ent study, we have found that there is a large clonal variation
in the IL-1 augmentation of fatty acid release. Some hGIIA-
transfected HEK293 cells are more responsive to IL-1 than
others (Fig. 5A), and some hGX-transfected HEK293 clones
show clear and reproducible IL-1 augmentation of [3H]ara-
chidonate release (Fig. 5B). In addition, we verified that hGX-
transfected cells secrete hGX and not hGIIA based on the
observation that the extracellular sPLA2 activity is blocked by
Me-Indoxam with an IC50 in the low micromolar range, con-
sistent with the published IC50 of 1–2 M for Me-Indoxam
acting on hGX, whereas the IC50 for Me-Indoxam acting on
hGIIA is much lower, 0.01–0.03 M (29). All together, the
newer results would seem to rule out a IL-1-glypican shut-
tling connection. The reason for this clonal variation is not
known, nor is the reason for the IL-1 effect. However, the
present results with two structurally distinct and potent
cPLA2- inhibitors show that the IL-1-dependent but not the
IL-1-independent component of [3H]arachidonate release in-
volves cPLA2- (Fig. 9). Furthermore, neither serum nor IL-1
leads to an increase in [3H]arachidonate release in cells not
transfected with hGIIA or hGX (Fig. 5), thus one concludes that
the IL-1-dependent fatty acid release involves the action of
both cPLA2- and sPLA2, whereas the IL-1-independent com-
ponents involves the action of sPLA2 alone. Based on immuno-
blot analysis, it has been suggested that HEK293 cells lack
cPLA2- (51), but other immunoblot results and the effect of
cPLA2- inhibitors (Fig. 10S) (52) clearly show the presence of
cPLA2- in these cells.
In the macrophage-like cell line p388D1, it has been sug-
gested that cPLA2- action leads to an intracellular pool of free
[3H]arachidonate accumulation, whereas the group V sPLA2 is
mainly responsible for accumulation of [3H]arachidonate in the
extracellular medium (53). In our studies with CHO-K1 and
HEK293 cells, it is clear that essentially all of the released
[3H]arachidonate is accounted for by that which accumulates in
the culture medium. Also the fact that the cPLA2- inhibitors
reduce accumulation of [3H]arachidonate in the medium in the
present as well as in previous studies (2, 26, 28, 42) argues that
free [3H]arachidonate liberated by cPLA2- transfers from the
cells to the culture medium. Also, lack of transfer of liberated
[3H]arachidonate from the inside of the cell to the culture
medium is clearly not the reason why HEK293 cells transfected
with hGIIA release [3H]arachidonate much more efficiently
than cells treated with exogenous addition of hGIIA.
The data presented in this paper provide a particularly clear
example of cross-talk between hGIIA or hGX and cPLA2-. A
second clear example of this cross-talk comes from the recent
study of Han et al. (15). They showed that expression of either
hGIIA or group V sPLA2 in cPLA2--deficient murine mesang-
ial cells does not lead to H2O2-stimulated [
3H]arachidonate
release, but expression of these sPLA2s augments [
3H]arachi-
donate release in mesangial cells that express cPLA2- above
the fatty acid release seen in cells containing cPLA2- but not
the sPLA2s. Both mitogen-activated protein kinase and protein
kinase C are involved in this sPLA2-dependent cPLA2- acti-
vation (15). Other studies have shown that exogenous addition
of sPLA2 to mammalian cells leads to activation of mitogen-
activated protein kinases along with activation of cPLA2- (for
example see Refs. 13, 14, and 54). In other cells, it has been
proposed that the lipolytic action of cPLA2- is required for the
lipolytic action of sPLA2s (for example see Refs. 55 and 56).
It must be stressed that none of these studies showing
sPLA2-cPLA2- cross-talk reveals the directionality of this
cross-talk, i.e. does cPLA2- allow sPLA2 to release fatty acids
or vice versa? However, it may be noted that Han et al. (15) and
Murakami et al. (18) showed that in H2O2-activated mesangial
cells and in serum/IL-1-stimulated, hGIIA-transfected
HEK293 cells, respectively, arachidonate is released in prefer-
ence to oleate. Because cPLA2- displays approximately 10-fold
selectivity for phospholipids with an sn-2 arachidonyl chain
versus and sn-2 oleoyl chain (1), whereas hGIIA displays es-
sentially no selectivity (29, 57), it would appear that in me-
sangial and HEK293 cells, cPLA2- is responsible for most of
the arachidonate release in the presence of H2O2 and serum/
IL-, respectively. The mechanism by which the action of
sPLA2 activates cPLA2- is under active investigation.
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Note Added in Proof—Recently, Arm and co-workers have shown
that disruption of the mouse group V sPLA2 gene leads to an 50%
reduction in the amount of arachidonic acid liberated from zymosan-
stimulated peritoneal macrophages (58), and yet earlier studies showed
that the disruption of the cPLA2- gene leads to complete loss of arachi-
donic acid from these cells (59). Thus, it appears that group V sPLA2
action somehow augments the function of cPLA2- in peritoneal macro-
phages. We have found that pyrrophenone blocks all of the arachido-
nate release from zymosan-stimulated mouse peritoneal macrophages,
but 1 and 10 M Me-Indoxam is without effect (data not shown). These
results are consistent with the gene disruption studies (58, 59) and
further suggest that mouse group V is able to augment the action of
cPLA2- and that the sPLA2 acts prior to release from the cells. Thus
our conclusions in the present study derived from transfected cells
appear to be relevant to at least some non-transfectant cells/agonist
systems.
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Arachidonic Acid Release from Mammalian Cells Transfected with Human Groups
IIA and X Secreted Phospholipase A2 Occurs Predominantly During the Secretory
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 Carine M. Mounier1, Farideh Ghomashchi1, Margaret R. Lindsay2, Scott James1, Alan G.
Singer1, Robert G. Parton2, and Michael H. Gelb1*
1Departments of Chemistry and Biochemistry, Campus Box 351700, University of
Washington, Seattle, WA 98195, USA
2Institute for Molecular Biosciences and Centre for Microscopy and Microanalysis and
School of Biomedical Sciences, University of Queensland, Brisbane, 4072, Queensland,
Australia
*Corresponding authors:  Michael H. Gelb (fax: 206-685-8665; email:
gelb@chem.washington.edu).
Supplemental Figures
Fig. 1S.  Release of hGIIA secreted from CHO-K1 cells into the culture medium by
extracellular heparin.  CHO-K1 cells transfected with hGIIA (clone 1, approximately 5
x 104 cells in 1 ml of medium) were washed with medium to remove non-cell surface
attached hGIIA.  Cells were incubated for 24 hr at 37 °C in medium containing the
indicated amount of heparin, and the amount of hGIIA enzymatic activity in the medium
was quantified using the fluorimetric assay.  The medium was removed and cells were
covered with medium containing 1 M NaCl.  After 15 min at 37 °C, the amount of hGIIA
enzymatic activity was quantified.  The Y-axis gives the amount of hGIIA enzymatic
activity released from the cell surface by heparin, expressed as a percentage of the total
enzymatic activity (heparin + salt solubilized).  It was found by trial and error that the
presence of heparin did not change the specific activity of hGIIA in the fluorimetric assay
(thus heparin-bound hGIIA can transfer to anionic substrate vesicles). The data shown is
representative of two independent experiments, each done in triplicate; the error bars
show the standard deviation from one of the triplicate analyses.
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Fig. 2S.  Salt dependance of release of secreted hGIIA from wild type and mutant
CHO-K1 cells.  Wild type (WT), pgsA-745 proteolygcan-deficient (PG-def.) and GPI-
LA1 GPI-deficient (GPI-def.) CHO-K1 cells transfected with hGIIA were cultured with
complete medium containing the indicated concentration of additional NaCl.  After 15
min at 37 °C, the culture medium was removed and stored at -20 °C until analyzed for
hGIIA enzymatic activity using the fluorimetric assay. The amount of hGIIA released
with 1 M NaCl was taken as 100% of the maximum releasable enzyme.  The values
shown for 0.12 M NaCl are those obtained with medium containing no additional salt.
The data shown is representative of two independent experiments, each done in triplicate;
the error bars show the standard deviation from one of the triplicate analyses.
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Fig. 3S.  Effect of Me-Indoxam on Arachidonate Release by Exogenously added
hGIIA-V3W.  The mutant hGIIA-V3W was added at 10 µg/ml to complete medium
above non-transfected CHO-K1 or HEK293 cells, and [3H]arachidonate released into the
culture medium was measured after 4 hrs at 37 °C.  Me-Indoxam was present at the
indicated concentrations and was added just prior to addition of enzyme.  The data shown
is representative of two independent experiments, each done in triplicate; the error bars
show the standard deviation from one of the triplicate analyses.
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Fig. 4S.  Distribution of extracellular hGIIA between the HEK293 cell surface and
the culture medium as a function of extracellular heparin concentration. Washed
hGIIA-transfected HEK293 cells (clone 1) were treated for 6 hr with the indicated
concentrations of heparin in complete medium containing IL-1?.  The medium was
removed and assayed for hGIIA enzymatic activity to determine the amount of enzyme.
The cells were washed with complete medium containing 1 M NaCl, and the amount of
hGIIA in the salt wash was determined as above. The data shown is representative of two
independent experiments, each done in triplicate; the error bars show the standard
deviation from one of the triplicate analyses.
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Fig. 5S.  Release of arachidonate by HEK293 cells treated with exogenous hGIIA
and hGX.  Non-transfected HEK293 cells were labeled with [3H]arachidonate, washed to
remove unincorporated fatty acid and treated with or without 2 ng/ml IL-1? for 15 hr at
37 °C in FBS-containing medium.  Recombinant hGIIA was added to the culture medium
(1 ml) to give 10 µg/ml, and cells were incubated for a further 6 hr at 37 °C in the
presence and absence of IL-1?.  Radioactivity released into the medium was quantified
(denoted Med.), and  [3H]arachidonate associated with the cells was quantified by
extraction with organic solvent and chromatography on a silica gel plate (denoted Cell).
Some cells were treated for 6 hr at 37 °C with 100 ng/ml recombinant hGX in the
presence and absence of 2 ng/ml IL-1?. The data shown is representative of three
independent experiments, each done in triplicate; the error bars show the standard
deviation from one of the triplicate analyses.
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Fig. 6S.  Time dependent accumulation of hGIIA in the culture medium of HEK293
cells.  Washed hGIIA-transfected HEK293 cells (clone 1) were cultured in complete
medium in the presence of 4 ng/ml IL-1? for 15 hr.  The medium was removed and
assayed with the fluorimetric sPLA2 assay to determine the amount of hGIIA.  Cells were
then washed three times with complete medium and then incubated for an additional 6 hr,
and the amount of hGIIA in the medium was quantified.  Heparin was absent during both
time periods (no heparin data), present at 0.5 mg/ml only during the 15 hr period (heparin
15 hr), or present only during the 6 hr period (heparin 6hr). The data shown is
representative of three independent experiments, each done in triplicate; the error bars
show the standard deviation from one of the triplicate analyses.
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Fig. 7S. Effect of heparin on arachidonate release by HEK293 cells transfected with
hGIIA.  Panel A is for clone 1 and panel B is for clone 3.  Cells were cultured for 15 hr
in the presence of FBS in the absence of IL-1? and then stimulated for 6 hr in the
presence or absence of FBS and 4 ng/ml IL-1? (as indicated).  High molecular weight
heparin (0.5 mg/ml) was present during the first 15 hr only, during the subsequent 6 hr
per only, during both periods (21 hr) or not present at all (as indicated).  Cells were
washed after the first 15 hr period, thus only [3H]arachidonate released during the
subsequent 6 hr period was measured.  The data shown is representative of three
independent experiments, each done in triplicate; the error bars show the standard
deviation from one of the triplicate analyses.
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Fig. 8S. Effect of heparin on arachidonate release by HEK293 cells transfected with
hGX.  Panel A is for clone 2 and panel B is for clone 3.  Cells were cultured for 15 hr in
the presence of FBS and then stimulated for 6 hr in the presence or absence of FBS and 4
ng/ml IL-1? (as indicated).  High molecular weight heparin (0.5 mg/ml) was present
during the first 15 hr only, during the subsequent 6 hr per only, during both periods (21
hr) or not present at all (as indicated). The data shown is representative of three
independent experiments, each done in triplicate; the error bars show the standard
deviation from one of the triplicate analyses.
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Fig. 9S. Me-Indoxam does not penetrate into HEK293 cells.  Non-transfected
HEK293 cells were incubated in serum-free medium with either 5 µM [3H]Me-Indoxam,
0.05 µM 1-[3H]-D-mannitol, or 0.05 µM 4-[3H]-L-propranolol for 20 min at 37 °C and
then centrifuged through a layer of 100% FBS.  Plotted is the percent of total
radioactivity present in the tube that reached the bottom of the tube as a function of the
number of cells incubated with the radiolabeled compound:  (?) Me-Indoxam, (?)
mannitol, (?) propranolol, (?) theoretical curve assuming a cell radius of 10 microns.
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Fig. 10S.  Immunoblot analysis of cPLA2-?  in HEK293 cells.  Top blot: non-
transfected cells minus IL-1? (lane 1), non-transfected cells plus IL-1? (lane 2), hGX-
transfected clone 2 minus IL-1? (lane 3), hGX-transfected clone 2 plus IL-1? (lane 4),
hGX-transfected clone 3 minus IL-1? (lane 5), non-transfected minus IL-1? plus 1 ng
cPLA2-? (lane 6), 1 ng cPLA2-? (lane 7). Bottom blot: hGX-transfected clone 3 plus IL-
1? (lane 8), hGIIA-transfected clone 1 minus IL-1? (lane 9), hGIIA-transfected clone 1
plus IL-1? (lane 10), hGIIA-transfected clone 4 minus IL-1? (lane 11), hGIIA-
transfected clone 4 plus IL-1? (lane 12), non-transfected cells plus IL-1?  plus 1 ng
cPLA2-? (lane 13), 1 ng cPLA2-? (lane 14).  The band migrating below cPLA2-? was
also seen with a second anti- cPLA2-? antiserum suggesting that it is a proteolytic cPLA2-
? fragment.  Virtually identical blots were obtained using HEK293 cells from the
American Type Culture Collection and from Invitrogen (EcR cell line, Cat. no. R640-07).
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Synthesis of [3H]Me-Indoxam.
2-Hydroxymethylbiphenyl.  2-Carboxybiphenyl (1.0 g, 5.05 mmol, Aldrich) was added
dropwise, as a solution in 10 mL of anhydrous Et2O, to a stirred mixture of 87 mg (2.17
mmol) of lithium aluminum hydride in 10 ml of anhydrous Et2O at room temperature.
After addition of the 2-carboxybiphenyl, the suspension was brought to a gentle reflux
and stirred overnight. TLC identified the major product at Rf  (Hexanes/EtOAc 3:2) = 0.6.
A small amount of the unreacted starting material was present, in addition to a small
amount of 2-formylbiphenyl. The mixture was quenched by the addition of 10 mL of
water at 0°C. Twenty mL of 20% H2SO4 was added to dissolve the aluminum salts. The
reaction mixture was extracted with Et2O (2 x 20 mL) and dried with Na2SO4. The
solvent was removed in vacuo to reveal a light yellow oil. The product was purified by
silica chromatography using a 60 mL fritted funnel with an increasing gradient of 10 –
20% EtOAc in Hexanes. 730 mg (79%) of a clear oil were obtained.  1H-NMR (200 MHz,
CDCl3): 7.53 – 7.32 (m, aryl, 9H), 4.56 (s, CH2OH, 2H).
2-Formylbiphenyl.  2-Hydroxymethylbiphenyl (300 mg, 1.63 mmol) was added as a
solution in 2 mL of anhydrous CH2Cl2 to a suspension of 3.0 g (34.5 mmol) of oven dried
MnO2 in 20 ml of anhydrous CH2Cl2. The reaction was stirred for 24 hours at room
temperature. The product was identified by TLC at Rf (Hexanes/EtOAc 3:2) = 0.9. A
small amount of the starting material was present at Rf = 0.6. Celite was added to the
reaction mixture, which was , and the filter cake was rinsed with 10 mL of CH2Cl2. The
filtrate was evaporated and dissolved in a small volume of hexanes (~4 mL). The sample
was chromatographed on silica in a 60 mL fritted funnel with hexanes as the eluant. A
clear oil (237 mg, 80%) was obtained. 1H-NMR (200 MHz, CDCl3): 10.0 (s, CHO, 1H),
8.07 – 7.36 (m, aryl, 9H).
Tritium labeled 2-hydroxymethylbiphenyl.  A 100 mCi sample of NaB[3H]4 (100 mCi, 80-
100 Ci/mmol, 1.0-1.25 µmol, American Radiolabeled Compounds) contained in an
ampule was placed inside a 100 mL two neck flask. The flask was flushed with N2 and
sealed with septa. The ampule was opened and a small stir bar was placed into the
ampule.  Unlabeled sodium borohydride (520 µg , 13. 8 µmol) was added to the ampule
in a solution of 100 µL of 0.01 N.  This solution was freshly prepared prior to use. To the
stirring solution of sodium borohydride was added 25 mg (138 µmol) of 2-
formylbiphenyl in a solution of 500 µL of iPrOH. The reaction was stirred for 8 hr. The
solution was quenched by the addition of 100 µL of 20% H2SO4, and the tritium gas was
trapped with a flask of Wilkinson’s catalyst in THF (connected via tygon tubing to the
reaction flask).  After stirring overnight, the reaction mixture was transferred to a 4 mL
vial and extracted with Et2O (4 x 500 µL). The combined organic phase was dried with a
small amount of Na2SO4. The solution was passed through a 9” Pasteur pipet containing a
plug of cotton, and 1 mL of ether was used to rinse the pipet. The filtrate was dried with a
stream of N2 to leave the crude reaction product. The mixture was taken up in 250 µL of
Hexanes/EtOAc (9:1) and purified on a silica gel column (9” pipet with a cotton plug),
eluting with the same solvent. Fractions containing the alcohol were combined and dried
using an N2 stream, and the product was immediately taken up in 500 µL of CH2Cl2. 4.2
of a clear oil were obtained (80 mCi, 3.5 Ci/mmol).
Tritium labeled 2-bromomethylbiphenyl. The CH2Cl2 solution of 2-
hydroxymethylbiphenyl was slowly added to a 4 mL vial containing 1 mL of 48% HBr
with stirring at 90°C. The reaction was stirred for 5 min. and then cooled for 5 min. After
cooling, 100 mg of ice was added to the vial. The solution was extracted with Et2O (4 x
500 µL), and the combined organic phase was dried with Na2SO4. The mixture was
filtered through cotton and dried with N2. The oil was immediately taken up in 200 µL of
hexanes and chromatographed on a silica column (9” Pasteur pipet with cotton plug) with
the same solvent as the eluant. The product was identified by co-migration on TLC with a
known standard (Rf (hexanes) = 0.5) and by the formation of a pink complex with I2
development of the TLC plate. The fractions containing the product were combined in a 4
mL vial and dried with N2 to give 4.1 mg (73%, 58 mCi) of the bromide as a clear oil.
The oil was taken up in 500 µL of anhydrous THF.  1H-NMR (200 MHz, CDCl3): 7.55 –
7.22 (m, aryl, 9H), 4.45 (s, CH2Br,2H).
Tritium labeled t-butyl ester of Me-Indoxam. tert-Butyl 4-({3-[amino(oxo)acetyl]-2-
methyl-3H-indol-5-yl}oxy)butanoate (1) (12.0 mg, 36.0 µmol) was weighed into a flame
dried 4 mL vial.  Anhydrous THF (2.0 mL) was added, and the solution was stirred under
argon. NaH (95%, 2.5 mg, 60.0 µmol, Aldrich) was added to the vial and the mixture
allowed to stir for ten minutes at room temperature (it is imperative that the can of NaH
be freshly opened as old NaH contains NaOH, which will saponify and decarboxylate the
desired reaction product).  After ten minutes, 500 µL of the bright yellow suspension (9
µmol of sodiated indole) was added to a vial containing a THF solution of the
radiolabeled 2-bromomethylbiphenyl. This mixture was allowed to stir for 2 hours at
60°C.   The reaction was quenched by the addition of 1000 µL of water and then
extracted with Et2O (4 x 500µL).  The combined organic phase was dried with Na2SO4.
The contents of the vial was filtered through cotton and dried with N2. The solid was
immediately taken up in 250 µL of EtOAc/Hexanes (5:4) and chromatographed on a
Pasteur pipet column of silica gel with the same solvent. The product was identified by
co-migration with authentic Me-Indoxam on a silica TLC plate:  Rf (EtOAc/Hexanes 3:2)
= 0.4. The fractions containing the product were combined and dried using N2. The
product was taken up in ether for storage at – 20°C, or immediately submitted to
deprotection.
[3H]Me-Indoxam.  The solid tert-butyl ester was reacted with 500 µL of trifluoroacetic
acid in a 4 mL vial for 5 min at room temperature. The solvent was evaporated with an N2
stream, and 500 µL of CH2Cl2 was added and similarly evaporated, and this was repeated
to ensure complete removal of excess trifluoroacetic acid.  The sample was dissolved in
800 µL of MeOH. This solution was separated into two small vials and 100 µL of
deionized water was added to each sample. The samples were individually
chromatographed using C18 reverse-phase HPLC (Vydac 218TP1010 column
equilibrated with 70% solvent A (H2O containing 0.06% trifluoroacetic acid):30%
solvent B (MeOH with 0.06% trifluoroacetic acid).  After injection of the compound, the
column was washed with the same solvent for 35 min, then  a linear gradient to solvent
A:solvent B (30:70) over 30 minutes was used to elute the compound.  [3H]Me-Indoxam
(1.7 mg after two injections) eluted as a sharp peak (absorbance monitored at 263 nm) at
61 min.
The specific radioactivity of [3H]Me-Indoxam (680 Ci/mole) was obtained from
the concentration of compound (determined by human group IIA phospholipase A2
inhibition assay as described (2), using a standard curve prepared from non-radiolabeled
Me-Indoxam) and from the amount of radioactivity determined by liquid scintillation
counting.
Estimate for the rate of release of Me-Indoxam from cell membranes.   With certain
assumptions, it is possible to obtain a rough estimate for the rate constant for the
desorption of Me-Indoxam from membrane bilayers into the aqueous phase.  The
solubility limit of Me-Indoxam in water is of the order of 50 µM.  Thus with 50 µM Me-
Indoxam in water, about half of it is present as monomers and about half is present as
aggregates.  The rate  of monomers forming aggregates and the rate of aggregated
molecules forming monomers are equal at equilibrium.  If we assume that Me-Indoxam
molecules favor partitioning from the water layer into a self-aggregate with the same
energetics as the partitioning from the water layer into phospholipid membrane bilayers,
we can say that in the presence of roughly 50 µM phospholipid, as vesicles, about half of
the Me-Indoxam will be in the water layer and half in the membrane.  Most small organic
molecules display a second-order rate constant for transfer from the aqueous phase to the
membrane phase, kon, close to the diffusion controlled limit of about 10
10 M-1 s-1 (3).  Thus
the following estimate for the dissociation rate constant for desorption of Me-Indoxam
from membranes into the aqueous phase is obtained:
koff = (50 x 10
-6 M) x (1010 M-1 s-1) = 5 x 105 s-1
Thus, it is estimated that Me-Indoxam desorps from membrane vesicles with a half-life
on the order of 1 µsec.
Caco-2 cell permeability studies.   
Caco-2 cells (TC7 clone) were grown in DMEM medium (Hyclone Cat. SH30003.04)
with 10% FBS and 50 U/ml penicillin G and 50 µg/ml streptomycin sulfate. Cells were
seeded at 105 per cm2 on porous polycarbonate membranes in 24-well Transwell plates
(Costar, Fisher Cat. 07-200-687).  Cells were fed every 2-3 days and once the day before
use, and permeability assays were typically performed 13-25 days post seeding.  Cells are
typically used for permeability assays for 20 consecutive passages in culture. For
permeability studies, the apical side was covered with Hank’s balanced salt solution
(containing Ca2+ and Mg2+) supplemented with 5 mM MES (pH adjusted to 6.5).  The
basolateral side contains Hank’s balanced salt solution supplemented with 5 mM HEPES
(adjusted to pH 7.4).  Me-Indoxam (50 µM) was added to the apical side for A-to-B
measurements or to the basolateral side for B-to-A measurements, and aliquots were
taken from both sides at 0 and 2 hr during incubation at 37 °C in a humidified atmosphere
with 5% CO2 with gentle shaking. 
14C-Mannitol (4 µM) is also present along with the test
compound to monitor the tightness of the cell monolayer junctions.
Aliquots of the culture medium were extracted with acetonitrile and analyzed by
combined HPLC/electrospray ionization mass spectrometry.  The M+H+ ion of Me-
Indoxam (443 AMU) was monitored, and the ion peak area was used together with a
standard curve to obtain the concentration of Me-Indoxam in the donor and acceptor
culture media. The apparent permeability (cm/sec) was calculated as follows (4):
Papp = [VR d[Me-Indoxam]/dt] [1/A(?C)]
Here, VR is the volume of the receiver chamber, d[Me-Indoxam]/dt is the rate of
appearance of Me-Indoxam (M/sec) on the acceptor side of the cell monolayer, A is the
surface area of the cell monolayer (cm2), and ?C is the Me-Indoxam concentration
gradient across the cell monolayer.  In the present studies, the amount of Me-Indoxam
passing across the cell layer was small compared to the total amount of compound, and
thus the above equation can be approximated as follows:
Papp = [VR x CR120/?t] [1/A(CD,mid – CR,mid)]
Here, CR120 is the concentration of Me-Indoxam in the receiver chamber at t = 120
min, ?t is the incubation time (120 min), CD,mid is concentration of Me-Indoxam on the
donor side at time 0 plus the concentration at t = 120 min divided by 2, and CR,mid is one-
half of the receiver side concentration of Me-Indoxam at t = 120 min.  Values of Papp
were also obtained for the test compounds, mannitol, vinblastin, and propranolol.
Immunoblot analysis of cPLA2-?.  HEK293 cells were scrapped from the culture plate,
pelleted by centrifugation, and washed with PBS.  To the cell pellet was added 20 µl of
ice-cold 66 mM HEPES, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 25 mM
PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and the cell suspension was stored at –80
°C. The cell suspension was thawed on ice, and subsequent steps were carried out at 4 °C.
The sample was transferred to a 15 ml Falcon tube, and cells were lysed by addition of
1/3 volume of 4X Laemmli sample buffer (1X Laemmli sample buffer is 63 mM Tris-
HCl, pH 6.8, 10% glycerol, 2% SDS).  The final volume of lysate was brought to 175 µl
by the addition of 1X Laemmli sample buffer.  The lysate was sonicated for 15 seconds
with a microtip at 50% power , 50% duty cycle.  The sample was centrifuged at for 20
min at 1,500 rpm (no precipitate was seen).  Sonication and centrifugation were repeated
once more.  The lysate was centrifuged in an Eppendorf microfuge at 14,000 rpm for 3
min at room temperature, and the supernatant was transferred to a new tube.  Protein
concentration was determined by the Bradford dye-binding assay (using BSA as a
standard), and 30 µg of per lane were resolved on a 7.9% acrylamide gel by SDS-PAGE.
Proteins were electro-transferred for 1 hr at 100 V to a polyvinylidene fluoride
microporous membrane in a transfer buffer consisting of 25 mM Tris base, 192 mM
glycine, 20% (v/v) methanol while cooling in ice-water.  cPLA2-? was detected with a
rabbit anti-cPLA2 antiserum (R11683, (5)) diluted 30,000 fold in buffer (150 mM NaCl, 5
mM EDTA, 50 mM Tris-HCl, pH 7.4, 0.05% Triton X-100, 0.25% Gelatin (BioRad Cat.
no. 170-6537)).  After washing the blot with the same buffer, HRP-conjugated secondary
antibody and ECL reagents (Amersham Biosciences) were used to detect cPLA2-?.
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